Details of Disease

General Information of Disease (ID: DIS5QJ9S)

• Disease Name: Bacterial infection
• Synonyms: infections, bacterial; bacterial disorder; bacterial infectious disease; Bacteria disease or disorder; Bacteria caused disease or disorder; bacterial disease; bacterial infection; infection, bacterial; Bacteria infectious disease
• Disease Class: 1A00-1C4Z: Bacterial infection
• Definition: An acute infectious disorder that is caused by gram positive or gram negative bacteria; representative examples include pneumococcal, streptococcal, salmonella, and meningeal infections.
• Disease Hierarchy:
  DISEM33Q: Infectious disease
  DIS5QJ9S: Bacterial infection
• ICD Code:
  ICD-11: ICD-11: 1A00-1C4Z
  ICD-10: ICD-10: A00-B99
  Expand ICD-11: '1C41
  Expand ICD-10: 'A02.9; 'A03.8; 'A30-A49; 'A49; 'A49.0; 'A49.1; 'A49.2; 'A49.3; 'A49.8; 'A49.9; 'B37.7
• Disease Identifiers:
  MONDO ID: MONDO_0005113
  MESH ID: D001424
  UMLS CUI: C0004623
  MedGen ID: 14012
  SNOMED CT ID: 87628006

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 185 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Alatrofloxacin mesylate	DM5H88N	Approved	Small molecular drug	[1]
Amdinocillin	DMIG6FY	Approved	Small molecular drug	[2]
Amikacin	DM5PDRB	Approved	Small molecular drug	[3]
Amoxicillin	DMUYNEI	Approved	Small molecular drug	[4]
Ampicillin	DMHWE7P	Approved	Small molecular drug	[5]
Apalcillin sodium	DMJ6IS5	Approved	Small molecular drug	[1]
Arbekacin	DMHTXSL	Approved	Small molecular drug	[6]
Aspoxicillin	DM86LZA	Approved	Small molecular drug	[1]
Astromycin sulfate	DMUHBIK	Approved	Small molecular drug	[1]
Aztreonam	DMDNJHG	Approved	Small molecular drug	[7]
B-Lactams	DMR8YD6	Approved	Small molecular drug	[8]
Bacampicillin	DMP54C7	Approved	Small molecular drug	[9]
Benzalkonium chloride	DM01N1A	Approved	NA	[1]
Benzylpenicilloyl Polylysine	DMQHM2D	Approved	Small molecular drug	[10]
Biapenem	DMWWLOM	Approved	Small molecular drug	[11]
Brodimoprim	DMA9S85	Approved	Small molecular drug	[12]
Candicidin	DMNZSC1	Approved	Small molecular drug	[13]
Capreomycin	DMNZBRY	Approved	Small molecular drug	[14]
Carbenicillin Indanyl Sodium	DME2XG3	Approved	Small molecular drug	[1]
Carbol-fuchsin	DMDWBPG	Approved	NA	[1]
Carumonam	DMJIZZI	Approved	Small molecular drug	[1]
Cefacetrile	DMRSZA5	Approved	Small molecular drug	[15]
Cefaclor	DMJXDGC	Approved	Small molecular drug	[16]
Cefadroxil	DMMC345	Approved	Small molecular drug	[17]
Cefalotin	DMVYSLE	Approved	Small molecular drug	[18]
Cefatrizine	DMGGRTQ	Approved	Small molecular drug	[1]
Cefazolin	DMPDYFR	Approved	Small molecular drug	[19]
Cefbuperazone sodium	DM17H5B	Approved	Small molecular drug	[7]
Cefcapene pivoxil	DMO3YVA	Approved	Small molecular drug	[7]
Cefdinir	DMJ7A0H	Approved	Small molecular drug	[4]
Cefditoren	DMSUVM1	Approved	Small molecular drug	[7]
Cefepime	DMHVWIK	Approved	Small molecular drug	[7]
Cefetamet pivoxil hcl	DMVY1VX	Approved	Small molecular drug	[7]
Cefixime	DMY60I8	Approved	Small molecular drug	[7]
Cefmenoxime	DMPLY7B	Approved	Small molecular drug	[7]
Cefmetazole	DM42W1B	Approved	Small molecular drug	[20]
Cefminox sodium	DM0NEF7	Approved	Small molecular drug	[7]
Cefodizime sodium	DMCWL06	Approved	Small molecular drug	[7]
Cefonicid	DMTX2BH	Approved	Small molecular drug	[7]
Cefoperazone	DM53PV8	Approved	Small molecular drug	[7]
Ceforanide	DMSQVD6	Approved	Small molecular drug	[7]
Cefoselis	DMW6TXN	Approved	Small molecular drug	[7]
Cefotaxime	DMEB837	Approved	NA	[21]
Cefotetan	DM07TX3	Approved	Small molecular drug	[7]
Cefoxitin	DMY8NC4	Approved	NA	[7]
Cefpiramide	DMZ2WL4	Approved	Small molecular drug	[7]
Cefpirome sulfate	DMLNKY5	Approved	Small molecular drug	[7]
Cefpodoxime	DMJUNY5	Approved	Small molecular drug	[7]
Cefprozil	DM7DSYP	Approved	Small molecular drug	[7]
Cefradine	DMUNSWV	Approved	Small molecular drug	[22]
Cefroxadine	DMS1GKC	Approved	Small molecular drug	[1]
Cefsoludin sodium	DMD6VQT	Approved	Small molecular drug	[1]
Ceftazidime	DM41GRA	Approved	Small molecular drug	[7]
Cefteram pivoxil	DMY1E0B	Approved	Small molecular drug	[7]
Ceftiofur	DMR2SOZ	Approved	Small molecular drug	[1]
Ceftizoxime	DM3VOGS	Approved	Small molecular drug	[7]
Ceftriaxone	DMCEW64	Approved	Small molecular drug	[23]
Cefuzonam sodium	DMV4IU0	Approved	Small molecular drug	[7]
Cephalexin	DMD5JU8	Approved	Small molecular drug	[24]
Cephaloglycin	DMYZITL	Approved	Small molecular drug	[25]
Cephalosporin	DM79XDW	Approved	Small molecular drug	[26]
Cephalothin Sodium	DM51Z9E	Approved	Small molecular drug	[1]
Chloramphenicol	DMFXEWT	Approved	Small molecular drug	[8]
Chlorhexidine	DMQ9MVG	Approved	Small molecular drug	[27]
Cilastatin	DME2H5T	Approved	Small molecular drug	[28]
Ciprofloxacin XR	DM2NLS9	Approved	Small molecular drug	[1]
Clarithromycin	DM4M1SG	Approved	Small molecular drug	[7]
Clavulanate	DM2FGRT	Approved	Small molecular drug	[29]
Clomocycline	DM0ZRMQ	Approved	Small molecular drug	[30]
Clostridium butyricum MIYAIRI 588	DMS1RJG	Approved	NA	[1]
Cloxacillin	DMUTL7O	Approved	Small molecular drug	[31]
Cyclacillin	DMHSJB4	Approved	Small molecular drug	[32]
Cycloserine	DMT1I52	Approved	Small molecular drug	[8]
Dalbavancin	DMGMNH3	Approved	Small molecular drug	[33]
Dalfopristin	DM4LTKV	Approved	Small molecular drug	[7]
Daptomycin	DMFDQ3I	Approved	NA	[34]
Dicloxacillin	DM8EU0Z	Approved	Small molecular drug	[35]
Dirithromycin	DM0D9YJ	Approved	Small molecular drug	[7]
Epicillin	DMDTTOS	Approved	Small molecular drug	[1]
Ertapenem	DM4S3O8	Approved	Small molecular drug	[7]
Erythromycin	DM4K7GQ	Approved	Small molecular drug	[36]
Fleroxacin	DMXGQYZ	Approved	Small molecular drug	[37]
Flomoxef sodium	DMS220L	Approved	Small molecular drug	[7]
Flucloxacillin	DMNUWST	Approved	Small molecular drug	[38]
Flurithromycin ethylsuccinate	DMX2XSL	Approved	Small molecular drug	[7]
Fosfomycin	DMVGPMX	Approved	Small molecular drug	[8]
Framycetin	DMF8DNE	Approved	Small molecular drug	[39]
Furazolidinone	DM7DBOY	Approved	NA	[1]
Fusidic Acid	DMWVCF3	Approved	Small molecular drug	[8]
Gemifloxacin	DMHT34O	Approved	Small molecular drug	[3]
Gentamicin	DMKINJO	Approved	Small molecular drug	[40]
Gentamicine sulfate	DMBT7MI	Approved	Small molecular drug	[34]
Gentian violet	DMAPVRR	Approved	Small molecular drug	[1]
Gramicidin D	DMPT74U	Approved	Small molecular drug	[41]
Grepafloxacin	DMGLX0T	Approved	Small molecular drug	[42]
Hetacillin	DMPXITB	Approved	Small molecular drug	[1]
Hexachlorophene	DMLKSE0	Approved	Small molecular drug	[43]
Imipenem	DMI9FBP	Approved	Small molecular drug	[34]
Isepamicin	DMKDRO9	Approved	Small molecular drug	[1]
Isoxyl	DMJL10P	Approved	Small molecular drug	[8]
Josamycin	DMKJ8LB	Approved	Small molecular drug	[44]
Kanamycin	DM2DMPO	Approved	Small molecular drug	[14]
Latamoxef	DMANL0D	Approved	Small molecular drug	[45]
Lenampicillin hci	DMA0TL2	Approved	Small molecular drug	[1]
Levofloxacin	DMS60RB	Approved	Small molecular drug	[34]
Linezolid	DMGFPU2	Approved	Small molecular drug	[46]
Lomefloxacin	DMVRH9C	Approved	Small molecular drug	[47]
Loracarbef	DM4L8H3	Approved	Small molecular drug	[7]
Lymecycline	DMOMLHJ	Approved	Small molecular drug	[48]
Macrolides	DM3BS97	Approved	Small molecular drug	[8]
Meclocycline	DMSFQ8I	Approved	Small molecular drug	[49]
Meningitec	DMT8EC0	Approved	NA	[1]
Meropenem	DM62UHC	Approved	Small molecular drug	[7]
Methacycline	DMAY96V	Approved	Small molecular drug	[50]
Meticillin	DMIKHN0	Approved	Small molecular drug	[51]
Micronomicin sulfate	DMX0T3B	Approved	Small molecular drug	[1]
Midecamycin	DMES7JY	Approved	Small molecular drug	[1]
Minocycline	DMVN5OH	Approved	Small molecular drug	[52]
Moxalactam Disodium	DMYKUNR	Approved	Small molecular drug	[1]
Moxifloxacin	DMU8V4S	Approved	Small molecular drug	[14]
Mupirocin	DMWX683	Approved	Small molecular drug	[8]
Netilmicin	DMRD1QK	Approved	Small molecular drug	[7]
Nifurzide	DMPGOR1	Approved	Small molecular drug	[1]
Nitrofurazone	DMSM2KE	Approved	Small molecular drug	[53]
Norfloxacin	DMIZ6W2	Approved	Small molecular drug	[54]
Novobiocin	DMRFWGK	Approved	Small molecular drug	[34]
Ofloxacin	DM0VQN3	Approved	Small molecular drug	[4]
Omadacycline	DMR2J95	Approved	NA	[55]
Oritavancin	DM28D05	Approved	Small molecular drug	[33]
Oxacillin	DMTAFY4	Approved	Small molecular drug	[56]
Oxidized glutathione	DM9EQC0	Approved	Small molecular drug	[57]
Oxytetracycline	DMOVH1M	Approved	Small molecular drug	[58]
Ozenoxacin	DM6KZMG	Approved	NA	[59]
Panipenem	DMOJFZD	Approved	Small molecular drug	[1]
Penicillin	DMNMHBV	Approved	Small molecular drug	[60]
Penicillin G Benzathine	DM49VEW	Approved	Small molecular drug	[1]
Penicillin G Procaine	DMU4JLB	Approved	Small molecular drug	[1]
Penicillin G Sodium	DMY18XK	Approved	Small molecular drug	[1]
Penicillin V	DMKVOYF	Approved	Small molecular drug	[34]
Penicillin V Potassium	DM8LX76	Approved	Small molecular drug	[1]
Piperacillin	DMTBKF3	Approved	Small molecular drug	[61]
Pivampicillin	DMX8CVY	Approved	Small molecular drug	[62]
Povidone-iodine	DMD4XOS	Approved	Small molecular drug	[1]
Pristinamycin	DM0VV1R	Approved	Small molecular drug	[1]
Propicillin	DMWDHUZ	Approved	Small molecular drug	[1]
Quinolones	DM5GVHU	Approved	Small molecular drug	[63]
Quinupristin	DMLKFC4	Approved	Small molecular drug	[7]
Rabeprazole	DMMZXIW	Approved	Small molecular drug	[64]
RBPI-21	DMCFZKD	Approved	NA	[1]
Rifamycin b	DMK4DKM	Approved	Small molecular drug	[1]
Rifaximin	DMW1TV2	Approved	Small molecular drug	[65]
Rokitamycin	DMCZWOK	Approved	Small molecular drug	[1]
Rosoxacin	DMVOIK1	Approved	Small molecular drug	[66]
Rv-11	DMOWPQV	Approved	Small molecular drug	[1]
Silver sulfadiazine	DMVTHWQ	Approved	Small molecular drug	[67]
Sparfloxacin	DMB4HCT	Approved	Small molecular drug	[68]
Spectinomycin	DM0MQ35	Approved	Small molecular drug	[69]
Spiramycin	DM20R5F	Approved	Small molecular drug	[1]
Streptomycin	DME1LQN	Approved	Small molecular drug	[70]
Sulbactam sodium	DMHSR3R	Approved	Small molecular drug	[1]
Sulfamerazine	DMKM3SX	Approved	Small molecular drug	[71]
Sulfameter	DMCQYBZ	Approved	Small molecular drug	[1]
Sulfamethazine	DMRGZ16	Approved	Small molecular drug	[72]
Sulfamethoxazole	DMB08GE	Approved	Small molecular drug	[1]
Sulfamylon	DMIO1K0	Approved	Small molecular drug	[1]
Sulfanilamide	DMABVE9	Approved	Small molecular drug	[73]
Sulfaphenazole	DMFNAEM	Approved	Small molecular drug	[1]
Sulfonamides	DM1YA7M	Approved	Small molecular drug	[8]
Sultamicillin tosilate	DMRDQ1Q	Approved	Small molecular drug	[1]
Tazobactam	DM3XNUI	Approved	Small molecular drug	[7]
Teicoplanin	DMAQ2LK	Approved	Small molecular drug	[1]
Telithromycin	DMZ4P3A	Approved	Small molecular drug	[74]
Tetracycline	DMZA017	Approved	Small molecular drug	[34]
Tetrodotoxin	DMWMPRG	Approved	Small molecular drug	[75]
Thiamphenicol	DMDRKH2	Approved	Small molecular drug	[1]
Ticarcillin	DM4ME02	Approved	Small molecular drug	[76]
Tindamax	DM3OWT4	Approved	Small molecular drug	[77]
Tobramycin	DMUI0CH	Approved	Small molecular drug	[34]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[78]
Troleandomycin	DMUZNIG	Approved	Small molecular drug	[79]
Trovafloxacin	DM6AN32	Approved	Small molecular drug	[80]
Viomycin sulfate	DMZYLFC	Approved	Small molecular drug	[1]
Virginiamycin	DMSWYI7	Approved	Small molecular drug	[1]
Zinforo	DMAKEJZ	Approved	Small molecular drug	[81]
OLANEXIDINE HYDROCHLORIDE	DMQCGN8	Registered	Small molecular drug	[82]

This Disease is Treated as An Indication in 74 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABT-492	DMJFD2I	Phase 3	Small molecular drug	[83]
AZD0914	DMM6G5D	Phase 3	NA	[84]
Cefluprenam	DMLWIU4	Phase 3	Small molecular drug	[85]
Cethromycin	DMIGX84	Phase 3	Small molecular drug	[34]
CRL-8131	DMCIY7N	Phase 3	Small molecular drug	[86]
FemiVac	DM8SW6K	Phase 3	NA	[87]
Iclaprim	DM7YNV9	Phase 3	Small molecular drug	[34]
Iseganan	DMJE6N7	Phase 3	NA	[88]
LBVH-0101	DMAFZF1	Phase 3	NA	[89]
Oglufanide	DMAZ6TP	Phase 3	Small molecular drug	[90]
Omiganan	DM7UF9M	Phase 3	NA	[91]
Ramoplanin	DMYLAIG	Phase 3	NA	[92]
Rifalazil	DMYXOHV	Phase 3	Small molecular drug	[93]
Shigamabs	DM4N1SP	Phase 3	Monoclonal antibody	[94]
STI-001	DME0XSP	Phase 3	NA	[95]
Ushercell	DMM2OZH	Phase 3	Small molecular drug	[96]
LACTIN-V	DMOAPGT	Phase 2/3	NA	[97]
Staphylococcus aureus vaccine	DMRBA5F	Phase 2/3	NA	[98]
AFN-1720	DM6AJKC	Phase 2	NA	[99]
AIC499	DMQ7W5E	Phase 2	Small molecular drug	[100]
ATM AVI	DM7I56B	Phase 2	NA	[101]
AZD-2563	DMIQD44	Phase 2	Small molecular drug	[102]
BC-3781 intravenous	DMY1UGV	Phase 2	Small molecular drug	[103]
BOS-228	DMZ70GE	Phase 2	Small molecular drug	[104]
CG-400549	DMFAKGR	Phase 2	Small molecular drug	[105]
E-1101	DMDFKPY	Phase 2	NA	[106]
EDP-420	DM5WZ0O	Phase 2	Small molecular drug	[107]
GSK1322322	DM1EPMF	Phase 2	NA	[108]
Lenapenem hydrochloride hydrate	DMZKBMG	Phase 2	Small molecular drug	[109]
LTX-109	DMXEQ0R	Phase 2	Small molecular drug	[110]
MK-7655	DMLMV0O	Phase 2	Small molecular drug	[111]
N-chlorotaurine	DMZBUMO	Phase 2	Small molecular drug	[112]
NPI-32101	DMB79ZR	Phase 2	NA	[113]
POL-7080	DMVCN8G	Phase 2	NA	[114]
SQ-109	DMWK9BX	Phase 2	Small molecular drug	[115]
Sulopenem etzadroxil	DMSJVFC	Phase 2	Small molecular drug	[116]
Tefibazumab	DM3SSOP	Phase 2	Monoclonal antibody	[117]
VEN100	DMT32TW	Phase 2	NA	[118]
WCK-771	DMVQARP	Phase 2	Small molecular drug	[119]
Anthrax Immune Globulin (AIG)	DMW5P68	Phase 1/2	NA	[120]
Antimicrobial oral vaccine	DM2L79L	Phase 1/2	NA	[121]
AV0328	DMH1Z10	Phase 1/2	NA	[121]
HLF 1-11	DMDFG1O	Phase 1/2	Peptide	[122]
Nu-3	DM1KUOR	Phase 1/2	NA	[95]
PF-5230894	DMIYXZB	Phase 1/2	NA	[123]
RUT58-60	DMFIL93	Phase 1/2	NA	[124]
StaphTAME	DMFBDTM	Phase 1/2	NA	[125]
BAL-30072	DM5KU30	Phase 1	Small molecular drug	[126]
BMY-43748	DMW8VEH	Phase 1	Small molecular drug	[127]
DZ-2640	DMS1NC8	Phase 1	NA	[128]
EDP-322	DMWTVM1	Phase 1	NA	[129]
EDP-788	DMGRCTF	Phase 1	Small molecular drug	[130]
Friulimicin	DMUI8F3	Phase 1	NA	[131]
GE-1170A	DMMF6UB	Phase 1	NA	[132]
Ge2270a	DMJK7V0	Phase 1	Small molecular drug	[133]
H-100	DMYLGPO	Phase 1	Small molecular drug	[134]
IDP-204040	DM5A8TA	Phase 1	NA	[135]
IDR-1018	DM1RNT7	Phase 1	NA	[136]
Lotilibcin	DMDLTCU	Phase 1	NA	[137]
ME-1071	DMEMQ5J	Phase 1	NA	[138]
OP-0595	DMECVP9	Phase 1	Small molecular drug	[139]
PB-6	DM54YEH	Phase 1	NA	[140]
QPX7728	DMEXZQ2	Phase 1	Small molecule	[141]
REP8839	DMZJH23	Phase 1	Small molecular drug	[142]
RG6006	DMJWWXH	Phase 1	Peptide	[143]
S. aureus type 336 vaccine	DM74N1O	Phase 1	NA	[144]
SC-002	DMZ3HD1	Phase 1	NA	[145]
TRL1068	DML197E	Phase 1	Antibody	[146]
Valortim	DMYAIUB	Phase 1	Antibody	[147]
VNRX-5133	DMNZ6XH	Phase 1	Small molecular drug	[148]
W-205GBA2ED	DM320LY	Phase 1	NA	[149]
WF-11605	DM57FHW	Phase 1	Small molecular drug	[150]
XNW4107	DMT0747	Phase 1	Small molecule	[151]
Kirromycin	DML9UFD	Clinical trial	Small molecular drug	[152]

This Disease is Treated as An Indication in 127 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Fusafungine	DM53UIC	Withdrawn from market	Small molecular drug	[1]
Roxithromycin	DMVMIK2	Withdrawn from market	Small molecular drug	[153]
Temafloxacin	DM3TON2	Withdrawn from market	Small molecular drug	[154]
Tetramune	DMCMW8H	Withdrawn from market	NA	[155]
Cefaclidine	DMJPG2G	Discontinued in Preregistration	Small molecular drug	[156]
Trospectomycin	DMI1AIB	Discontinued in Preregistration	Small molecular drug	[157]
CEFCANEL DALOXATE HYDROCHLORIDE	DMANMXZ	Discontinued in Phase 3	Small molecular drug	[158]
CEFETECOL	DMEMUQP	Discontinued in Phase 3	Small molecular drug	[159]
CEFMATILEN HYDROCHLORIDE HYDRATE	DMBZNHA	Discontinued in Phase 3	Small molecular drug	[160]
Eperezolid	DMCU1WO	Discontinued in Phase 3	Small molecular drug	[161]
Evernimicin	DM159U2	Discontinued in Phase 3	Small molecular drug	[162]
Lamectacin	DM7RGFW	Discontinued in Phase 3	Small molecular drug	[163]
OLAMUFLOXACIN MESILATE	DM0O2HP	Discontinued in Phase 3	Small molecular drug	[164]
Sanfetrinem	DM3KC81	Discontinued in Phase 3	Small molecular drug	[165]
Veronate	DMVQD2A	Discontinued in Phase 3	NA	[166]
A-86719.1	DM7VSBH	Discontinued in Phase 2	Small molecular drug	[167]
BAY-Y-3118	DMCZKG0	Discontinued in Phase 2	Small molecular drug	[168]
Cadrofloxacin	DMHJ3SN	Discontinued in Phase 2	Small molecular drug	[169]
Campyvax	DMUI5XK	Discontinued in Phase 2	NA	[170]
Cefpiroxime	DMUB43I	Discontinued in Phase 2	NA	[171]
CFC-222	DMHK8IM	Discontinued in Phase 2	Small molecular drug	[172]
DANOFLOXACIN	DMF3E51	Discontinued in Phase 2	Small molecular drug	[173]
DX-619	DMSTA5L	Discontinued in Phase 2	Small molecular drug	[174]
EREMOMYCIN	DMYR5OX	Discontinued in Phase 2	NA	[175]
FANDOFLOXACIN HYDROCHLORIDE	DM8UC0K	Discontinued in Phase 2	Small molecular drug	[176]
HMR-3004	DMONA1W	Discontinued in Phase 2	NA	[177]
KP-736	DMM1SLF	Discontinued in Phase 2	Small molecular drug	[178]
PA-1806	DM4ZNKX	Discontinued in Phase 2	NA	[179]
Ro-23-9424	DM4YA63	Discontinued in Phase 2	Small molecular drug	[180]
Streptococcal B vaccine	DM5AOSG	Discontinued in Phase 2	NA	[181]
TMA-230	DMRPX5A	Discontinued in Phase 2	Small molecular drug	[182]
Tomopenem	DM1YXPL	Discontinued in Phase 2	Small molecular drug	[183]
Y-26611	DMY7G5W	Discontinued in Phase 2	Small molecular drug	[184]
YM-17K	DMIRSLV	Discontinued in Phase 2	NA	[185]
BRL-44154	DMIX9O0	Discontinued in Phase 1	NA	[186]
CAB-175	DMA6835	Discontinued in Phase 1	Small molecular drug	[187]
CB-182804	DMYCPF9	Discontinued in Phase 1	NA	[188]
Cefdaloxime pentexil tosilate	DMJVZ9O	Discontinued in Phase 1	NA	[189]
CEFTRAZONAL BOPENTIL	DMO075K	Discontinued in Phase 1	Small molecular drug	[190]
Cetefloxacin	DM85SYL	Discontinued in Phase 1	Small molecular drug	[191]
DC-159a	DMQMJVW	Discontinued in Phase 1	NA	[192]
DK-507k	DME5PXL	Discontinued in Phase 1	Small molecular drug	[193]
DS-8587	DMK1FBD	Discontinued in Phase 1	NA	[194]
DU-6681	DM9S51Q	Discontinued in Phase 1	NA	[195]
DV-7751A	DMDC4BA	Discontinued in Phase 1	Small molecular drug	[196]
E-4767	DM2QX4C	Discontinued in Phase 1	NA	[197]
E-5065	DMJSPO2	Discontinued in Phase 1	NA	[198]
EBS-A42	DM55463	Discontinued in Phase 1	NA	[181]
ER-35786	DM3LKAR	Discontinued in Phase 1	Small molecular drug	[199]
FK-041	DMVL5RC	Discontinued in Phase 1	NA	[200]
FK-518	DM96GQK	Discontinued in Phase 1	Small molecular drug	[201]
GR-108359	DM6QGX2	Discontinued in Phase 1	NA	[202]
GSK945237	DM2AP64	Discontinued in Phase 1	NA	[203]
GW-549771	DMZJ5M5	Discontinued in Phase 1	NA	[204]
HMR-3562	DMKA612	Discontinued in Phase 1	Small molecular drug	[205]
MC-02,479	DMRIK2Y	Discontinued in Phase 1	NA	[206]
P1025	DM9LE1I	Discontinued in Phase 1	Small molecular drug	[207]
PD-131112	DMVFGWM	Discontinued in Phase 1	Small molecular drug	[208]
PF-4064900	DMCHPZM	Discontinued in Phase 1	Small molecular drug	[209]
S-3578	DMOVS1Z	Discontinued in Phase 1	NA	[210]
A-11259	DMZ5NQP	Terminated	NA	[222]
A-364	DMKL482	Terminated	NA	[223]
A-70826	DM9X24J	Terminated	Small molecular drug	[224]
A-75729	DMC3MH5	Terminated	NA	[225]
AR-2474	DMY6NC7	Terminated	NA	[226]
AR-709	DMUI81C	Terminated	Small molecular drug	[227]
Argyrin B	DMX328V	Terminated	NA	[228]
BK-218	DM9IQR6	Terminated	Small molecular drug	[229]
BMY-40062	DM2TF9P	Terminated	Small molecular drug	[230]
BOF-12013	DMUH2YH	Terminated	NA	[231]
BRL-42715	DMBC12X	Terminated	Small molecular drug	[232]
CB-102930	DMZ3QHF	Terminated	NA	[233]
CBR-2092	DMJAGKY	Terminated	Small molecular drug	[234]
CFC-240	DM49KK7	Terminated	NA	[235]
CHIR-29498	DME7FQ4	Terminated	Small molecular drug	[236]
CL-186659	DMYML2N	Terminated	NA	[237]
CP-111905	DMF47R8	Terminated	NA	[238]
CP-67015	DMWFI4A	Terminated	Small molecular drug	[239]
CS-461	DMZG90L	Terminated	Small molecular drug	[240]
DACTIMICIN	DMZ8OMT	Terminated	Small molecular drug	[241]
DC-756	DMUTETI	Terminated	NA	[242]
DIAVERIDINE	DMB74CM	Terminated	Small molecular drug	[243]
Epiroprim	DM6IY4M	Terminated	Small molecular drug	[244]
Group B streptococcal vaccine	DMC69OU	Terminated	NA	[245]
HMR-3787	DMCHFIT	Terminated	Small molecular drug	[246]
HMR-4004	DMWQX0R	Terminated	NA	[247]
KB-5246	DM2LFYD	Terminated	Small molecular drug	[248]
Ketolides	DMQOH7K	Terminated	NA	[249]
L-695256	DMFPCOP	Terminated	Small molecular drug	[250]
L-742728	DMUD9Z1	Terminated	Small molecular drug	[251]
L-786392	DM06BS6	Terminated	NA	[252]
LB-10522	DMFP8L7	Terminated	NA	[253]
MC-02306	DM5GZVM	Terminated	NA	[254]
ME-1036	DMKFB8X	Terminated	Small molecular drug	[255]
Micacocidin A	DMG5GEV	Terminated	Small molecular drug	[256]
Munumbicins	DMCBJ6P	Terminated	NA	[257]
PA-2794	DMUNN9K	Terminated	NA	[258]
PD-117596	DMN1A70	Terminated	Small molecular drug	[259]
PD-155392	DMIR074	Terminated	NA	[260]
PLR-9	DMS7WKY	Terminated	NA	[261]
Protosufloxacin	DM57YO8	Terminated	NA	[262]
PTX-007011	DM89RT7	Terminated	NA	[263]
PTX-008313	DM84RHP	Terminated	NA	[263]
QA-241	DMQRDBY	Terminated	Small molecular drug	[264]
Ro-09-1227	DMUP4KP	Terminated	Small molecular drug	[265]
Ro-09-1428	DM1KPEH	Terminated	Small molecular drug	[266]
Ro-24-1882	DM72SD9	Terminated	NA	[267]
Ro-24-7341	DMBJEVB	Terminated	NA	[268]
Ro-24-8138	DMWU8HB	Terminated	NA	[269]
Ro-25-0534	DMG907P	Terminated	Small molecular drug	[270]
Ro-25-0993	DM7LMVS	Terminated	NA	[271]
Ro-25-1132	DM9PKE2	Terminated	NA	[272]
Ro-25-2016	DMLW17F	Terminated	NA	[273]
Ro-25-4835	DM4DW6G	Terminated	NA	[274]
Ro-25-6833	DM07ZSC	Terminated	Small molecular drug	[275]
Ro-44-3949	DMNY4QG	Terminated	NA	[276]
Ro-48-1220	DMXMP3D	Terminated	Small molecular drug	[277]
Ro-48-5545	DM7AUF2	Terminated	NA	[278]
Ro-48-8391	DMBZYVN	Terminated	NA	[279]
RU-59863	DMDUBR4	Terminated	NA	[280]
SB-236049	DM5JDH1	Terminated	Small molecular drug	[281]
Siderophore-conjugated monocarbams	DM6YVIJ	Terminated	NA	[282]
SK&F-104662	DMF4BRI	Terminated	NA	[283]
Sporeamicins	DMP54Y5	Terminated	NA	[284]
SYN-987	DMIAMWE	Terminated	NA	[285]
Thiomarinols	DMIBM6I	Terminated	NA	[286]
U-97456	DMT4KTQ	Terminated	NA	[287]

This Disease is Treated as An Indication in 13 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TAK-816	DMQA3FR	Application submitted	Vaccine	[211]
A-54145	DMQCEXU	Preclinical	NA	[212]
CSA-13	DM7JLQ5	Preclinical	Small molecular drug	[213]
Doxorubicin-hemoglobin conjugate	DMY6TIC	Preclinical	NA	[214]
IDC-7181	DMJRVXT	Preclinical	NA	[215]
PF-708093	DMNPUG5	Preclinical	NA	[216]
RANBEZOLID HYDROCHLORIDE	DMRZBM7	Preclinical	Small molecular drug	[217]
RWJ-416457	DMH1FRY	Preclinical	Small molecular drug	[218]
Rx-01	DMXAIPY	Preclinical	NA	[219]
RX-01-423	DM3AIQO	Preclinical	NA	[219]
S-(2-Aminophenyl)-L-cysteine S,S-dioxide	DM9Y05C	Preclinical	Small molecular drug	[220]
S-Phenyl-L-cysteine sulfoxide	DM32NMB	Preclinical	Small molecular drug	[220]
Viquidacin	DMS5LPF	Preclinical	Small molecular drug	[221]

This Disease is Treated as An Indication in 79 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
1-TDC	DMYJ8MI	Investigative	NA	[95]
ACH-2881	DMKPK4O	Investigative	NA	[95]
ACH-702	DMMNQE3	Investigative	Small molecular drug	[288]
AM-112	DM1EA2R	Investigative	Small molecular drug	[95]
Anti-SEB mabs	DMXVMY1	Investigative	Monoclonal antibody	[95]
Anti-sortase mab	DM3V8HH	Investigative	Monoclonal antibody	[95]
Anti-Staphylococcus enterotoxin B hyperimmune globulin	DMRR22N	Investigative	NA	[95]
Aom-0755	DMB85G5	Investigative	NA	[95]
Aom-0785	DMQMW4U	Investigative	NA	[95]
Apolipoprotein E-derived peptides	DM1ULD0	Investigative	NA	[95]
BL-6030	DM5MT4V	Investigative	NA	[95]
BMY-41802	DMRM60Q	Investigative	Small molecular drug	[95]
BPL-002	DM5L30A	Investigative	NA	[95]
C10-1040	DMFKCBW	Investigative	NA	[95]
Carbapenem antibacterials	DMSXPUG	Investigative	Small molecular drug	[95]
COL-2401	DMA7N13	Investigative	NA	[95]
DPD-207	DM029CC	Investigative	NA	[95]
DRH-12	DM4ZD4B	Investigative	NA	[95]
GE-37468A	DM7QXHS	Investigative	NA	[95]
GF-011802-00	DMFRJC2	Investigative	NA	[95]
Herbicide amitrole	DMM6AMB	Investigative	NA	[95]
IB-07A037	DMDKN5E	Investigative	NA	[95]
IB-08A099	DMFPIAA	Investigative	NA	[95]
IB-09A149	DMIZWT9	Investigative	NA	[95]
IC-50	DM7YTFY	Investigative	NA	[95]
IPP-203101	DMOU207	Investigative	NA	[95]
KALA-617	DMLD0KG	Investigative	NA	[95]
KBAB-401	DMIB0NI	Investigative	NA	[95]
LK-157	DMNLOBT	Investigative	Small molecular drug	[95]
LOR-220	DM71BIC	Investigative	Small molecular drug	[289]
MBS-105	DMAMBNA	Investigative	NA	[95]
MBX-500	DM1DSK2	Investigative	NA	[95]
MFQ	DM64GOJ	Investigative	Small molecular drug	[95]
Modified PT1.2	DMDCESS	Investigative	NA	[95]
MRLP-098	DM9S0IJ	Investigative	NA	[95]
MRSAid	DM403QR	Investigative	NA	[95]
MT-176	DMGI8DH	Investigative	NA	[95]
MT-274	DMRD9V0	Investigative	NA	[95]
MU-1140-S	DM14IBS	Investigative	NA	[95]
MufroSyn	DMR20W4	Investigative	NA	[95]
MUT-11931	DMH31JP	Investigative	NA	[95]
NAI-107	DMT9FGI	Investigative	NA	[95]
NOSO-74	DML9QN5	Investigative	NA	[95]
Nu-2	DM124A4	Investigative	Small molecular drug	[95]
NXB-4221	DM6ORA5	Investigative	NA	[95]
NXB-5886	DMAYJDO	Investigative	NA	[95]
NXL-105	DMHWK21	Investigative	NA	[95]
NXT-1021	DMNB68U	Investigative	NA	[95]
P-216CM	DMC6ZU7	Investigative	NA	[95]
Parasin I	DMOSQC9	Investigative	NA	[95]
PC-190723	DMDAVZA	Investigative	Small molecular drug	[95]
PC4708	DMAIU4M	Investigative	NA	[95]
Peptide-conjugated phosphorodiamidate morpholino oligomers	DM1CH9C	Investigative	NA	[95]
PHER-O2	DM1VP7J	Investigative	NA	[95]
Plant-derived antibacterials	DMAE8X5	Investigative	NA	[95]
PLATENSIMYCIN	DM9N0RH	Investigative	Small molecular drug	[290]
PM-181104	DMGROF0	Investigative	NA	[95]
PTX-007	DMYV7WH	Investigative	NA	[95]
Pulvomycin	DMC5VLK	Investigative	Small molecular drug	[95]
Pumiliotoxin 251D	DMY2F6T	Investigative	Small molecular drug	[34]
QX-30002222	DM1910Z	Investigative	NA	[95]
RMH-41	DMRM48P	Investigative	NA	[95]
RS-118641	DMMNGO3	Investigative	Small molecular drug	[95]
Rx-04	DMHRUX0	Investigative	NA	[95]
Rx-101005	DMWTR4L	Investigative	Small molecular drug	[95]
SAR-215500	DMXGTFW	Investigative	NA	[95]
SOM-0004	DMN6KMV	Investigative	NA	[95]
SOM-1025	DMVJS40	Investigative	NA	[95]
SPH-260-4	DMSDRMB	Investigative	NA	[95]
Staphylocide	DMFM95E	Investigative	NA	[95]
SYM-006	DMU5UO1	Investigative	NA	[95]
TP-101	DMVWOE7	Investigative	Small molecular drug	[95]
TP-102	DMFP0DW	Investigative	Small molecular drug	[95]
TP-103	DMZ737D	Investigative	Small molecular drug	[95]
TP-104	DMEICM3	Investigative	Small molecular drug	[95]
TP-2758	DMC51QY	Investigative	NA	[95]
TP-834	DMH8X1P	Investigative	NA	[95]
YC-12	DM3NON1	Investigative	NA	[95]
Zn-DPA-I	DMGJM25	Investigative	NA	[95]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 93 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CALCA	TTVSFJW	Limited	Biomarker	[292]
CASP1	TTCQIBE	Limited	Biomarker	[293]
CCR8	TTE836A	Limited	Altered Expression	[294]
CFD	TT8D13I	Limited	Altered Expression	[295]
ELANE	TTPLTSQ	Limited	Biomarker	[296]
FAF1	TTSKL3G	Limited	Biomarker	[297]
GPR174	TTYUB4M	Limited	Biomarker	[298]
HDAC11	TT8K17W	Limited	Biomarker	[299]
ITGAM	TTB69FJ	Limited	Biomarker	[300]
PTAFR	TTQL5VC	Limited	Biomarker	[301]
RNPEP	TTD74YX	Limited	Altered Expression	[302]
SMPD1	TTJTM88	Limited	Biomarker	[303]
THPO	TTCG5PE	Limited	Altered Expression	[304]
TLR9	TTSHG0T	Limited	Genetic Variation	[305]
ABCB11	TTUXCAF	moderate	Genetic Variation	[306]
BPI	TTXCSDR	moderate	Biomarker	[307]
CASP4	TT6KIOT	moderate	Biomarker	[308]
CASP5	TTWR48J	moderate	Altered Expression	[309]
CD58	TT5KSBY	moderate	Biomarker	[310]
CEACAM6	TTIGH2W	moderate	Biomarker	[311]
CHRNA7	TTLA931	moderate	Genetic Variation	[312]
DHPS	TTBO2A9	moderate	Biomarker	[313]
DNAJB1	TTPXAWS	moderate	Altered Expression	[314]
EIF2AK4	TT9U4EP	moderate	Biomarker	[315]
GLRX	TTRJCNG	moderate	Biomarker	[316]
GPR182	TTT23CG	moderate	Biomarker	[317]
GPR183	TTME5YJ	moderate	Biomarker	[318]
IL1RAP	TTWS50K	moderate	Altered Expression	[319]
IRAK3	TTBPJOK	moderate	Biomarker	[320]
LAMP2	TTULDG7	moderate	Biomarker	[321]
M6PR	TT95ICL	moderate	Altered Expression	[322]
MRGPRX2	TT3YV20	moderate	Biomarker	[323]
NCR1	TTQNRJM	moderate	Biomarker	[324]
PDE7A	TT1BC3A	moderate	Altered Expression	[325]
PKD2L1	TTAHD89	moderate	Biomarker	[326]
PRDX4	TTPBL9I	moderate	Altered Expression	[327]
RBCK1	TTIKUVC	moderate	Biomarker	[328]
SLC46A1	TTY8Z2E	moderate	Altered Expression	[325]
SLC5A1	TT2UE56	moderate	Biomarker	[329]
SREBF2	TTRQ4AP	moderate	Biomarker	[330]
STK38	TT27XFN	moderate	Biomarker	[331]
SYVN1	TT8XKYM	moderate	Biomarker	[332]
TAGLN2	TTP6BIJ	moderate	Biomarker	[333]
TLR6	TTWRI8V	moderate	Genetic Variation	[334]
BTK	TTGM6VW	Strong	Biomarker	[335]
C5	TTKANGO	Strong	Biomarker	[336]
CAMP	TTULOB6	Strong	Biomarker	[337]
CD14	TT6I7DC	Strong	Altered Expression	[338]
CEL	TTTRNQW	Strong	Biomarker	[339]
CFI	TT6ATLX	Strong	Biomarker	[340]
CFTR	TTRLZHP	Strong	Altered Expression	[341]
DEFB4A	TTIVY12	Strong	Altered Expression	[342]
DHFR	TTYZVDJ	Strong	Biomarker	[313]
F2RL1	TTQR74A	Strong	Biomarker	[343]
FABP5	TTNT2S6	Strong	Altered Expression	[344]
FCGR1A	TTZK4I3	Strong	Altered Expression	[345]
FCGR2A	TTXT21W	Strong	Genetic Variation	[346]
FFAR2	TT0FYAN	Strong	Altered Expression	[347]
HAMP	TTRV5YJ	Strong	Biomarker	[348]
IL17D	TTC5LTG	Strong	Altered Expression	[349]
IL22	TTLDX4N	Strong	Biomarker	[350]
IL23A	TTC1GLB	Strong	Biomarker	[351]
IL7	TT8FRMO	Strong	Biomarker	[352]
IRF3	TTYR7OH	Strong	Biomarker	[353]
ISG15	TTVOH3T	Strong	Biomarker	[354]
ITGAL	TT48WR6	Strong	Biomarker	[355]
ITGB2	TTIJWR7	Strong	Genetic Variation	[356]
KLRK1	TTLRN4A	Strong	Biomarker	[357]
LBP	TTVQJLY	Strong	Biomarker	[358]
LCN2	TTKTLAI	Strong	Biomarker	[359]
LILRB2	TTHC6XU	Strong	Altered Expression	[360]
LILRB4	TTREOKA	Strong	Altered Expression	[360]
LY96	TT8S9AV	Strong	Biomarker	[361]
LYZ	TTAOZBW	Strong	Biomarker	[362]
MAP3K7	TTJQT60	Strong	Biomarker	[363]
MYD88	TTB6Q2O	Strong	Biomarker	[364]
NLRC5	TTWZC78	Strong	Biomarker	[365]
NOD1	TTYSRXM	Strong	Biomarker	[366]
NOD2	TTYPUHA	Strong	Genetic Variation	[367]
PF4	TTSG7Q5	Strong	Biomarker	[368]
PLA2G1B	TT9V5JH	Strong	Biomarker	[369]
PLA2G2A	TTO8QRU	Strong	Biomarker	[369]
RIPK2	TTCQ2E5	Strong	Biomarker	[370]
SAA1	TTY0DN9	Strong	Biomarker	[371]
SIRT2	TTLKF5M	Strong	Biomarker	[372]
TBX21	TTNF9PH	Strong	Biomarker	[373]
TCL1A	TTUKRDV	Strong	Genetic Variation	[374]
TIRAP	TTKU0LS	Strong	Biomarker	[375]
TLR2	TTY7ZHS	Strong	Biomarker	[376]
TLR7	TTRJ1K4	Strong	Biomarker	[377]
TNFRSF13B	TTL9OD4	Strong	Biomarker	[378]
TRAF6	TTCDR6M	Strong	Genetic Variation	[379]
TREM1	TTHZQP0	Strong	Biomarker	[380]

This Disease Is Related to 5 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC6A13	DTX8KP0	Limited	Biomarker	[381]
SLC22A17	DTXI9E6	moderate	Biomarker	[382]
ATP12A	DT5NLZA	Strong	Altered Expression	[383]
SLC27A5	DT0TQS3	Strong	Biomarker	[339]
SLC9A6	DTN0JXW	Strong	Biomarker	[384]

This Disease Is Related to 5 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
WARS1	DEPVE0M	Limited	Biomarker	[385]
INPP4A	DEBJ2NL	moderate	Biomarker	[386]
LPO	DEHX1DZ	moderate	Biomarker	[387]
SMOX	DEOH5V3	moderate	Biomarker	[388]
AKR1C4	DEAJN47	Strong	Biomarker	[389]

This Disease Is Related to 144 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AIM2	OT86QUI8	Limited	Biomarker	[390]
ATG4B	OTQ4RNRM	Limited	Altered Expression	[391]
ATP5F1A	OT3FZDLX	Limited	Biomarker	[392]
ATP6V0D2	OTMOZJO0	Limited	Biomarker	[393]
CCL1	OT23NON8	Limited	Altered Expression	[294]
CEBPD	OTNBIPMY	Limited	Biomarker	[394]
FAM89A	OTNASAXT	Limited	Altered Expression	[395]
FCN3	OTPRENLS	Limited	Biomarker	[396]
IFI44L	OTXKORJP	Limited	Biomarker	[395]
IFNGR1	OTCTQBWW	Limited	Altered Expression	[397]
ITLN1	OT7ZLJVV	Limited	Biomarker	[398]
LAMTOR1	OTIBJBW9	Limited	Biomarker	[399]
MARCO	OT0NW2Q0	Limited	Biomarker	[400]
MUC5B	OTPW6K5C	Limited	Biomarker	[401]
NLRP12	OTGR132Z	Limited	Biomarker	[402]
PRF1	OTFVXD7H	Limited	Biomarker	[403]
PTX3	OTPXHRKU	Limited	Biomarker	[404]
RAB20	OTP9OOVS	Limited	Altered Expression	[405]
RIPK3	OTL1D484	Limited	Biomarker	[406]
RNF5	OTDQGI37	Limited	Genetic Variation	[391]
RUNX1T1	OT30DED5	Limited	Biomarker	[389]
SDC4	OTKUVUGZ	Limited	Biomarker	[407]
SERPINB9	OTJ811IF	Limited	Biomarker	[408]
SLAMF1	OTBTT3ZQ	Limited	Biomarker	[409]
SNAP29	OTT30ZON	Limited	Biomarker	[410]
TAX1BP1	OTGJMGJ9	Limited	Biomarker	[399]
TBCE	OTGBSTKS	Limited	Biomarker	[411]
TMEM201	OTZBZ4MC	Limited	Biomarker	[412]
TOLLIP	OTYEO4NR	Limited	Biomarker	[364]
ACOT7	OT7C68YV	moderate	Altered Expression	[413]
ACTBL2	OTD6B81U	moderate	Altered Expression	[413]
ALPK1	OTBW6SGD	moderate	Biomarker	[414]
ATP6AP2	OT0IABVV	moderate	Genetic Variation	[415]
AZU1	OTHXU264	moderate	Biomarker	[416]
BATF3	OTI61WXQ	moderate	Biomarker	[417]
BID	OTOSHSHU	moderate	Biomarker	[418]
C9	OT7I5FDX	moderate	Biomarker	[419]
CD300LB	OTVC407Y	moderate	Biomarker	[420]
CEBPE	OTKZA25M	moderate	Biomarker	[421]
CGAS	OTJYIXNB	moderate	Biomarker	[422]
CH25H	OT9S2BSW	moderate	Biomarker	[330]
CLDN2	OTRF3D6Y	moderate	Biomarker	[423]
CNOT8	OT6CMCS0	moderate	Biomarker	[424]
COLEC11	OT4GC46Y	moderate	Biomarker	[425]
CRIP1	OT0EICG3	moderate	Biomarker	[421]
CSRP1	OTUS7RM2	moderate	Biomarker	[421]
CST9	OT37U1C8	moderate	Biomarker	[426]
DEFA5	OT95CBQ9	moderate	Biomarker	[427]
DOCK2	OTZTS3PA	moderate	Biomarker	[428]
DUSP12	OT8WB1YB	moderate	Biomarker	[429]
ECSIT	OTJX1YC7	moderate	Genetic Variation	[379]
EMP1	OTSZHUHQ	moderate	Biomarker	[430]
FBL	OTRODIE5	moderate	Altered Expression	[431]
FCMR	OTI7I47T	moderate	Biomarker	[432]
FERMT3	OTFQOT3C	moderate	Genetic Variation	[433]
FLVCR1	OT9XCFOC	moderate	Biomarker	[434]
GBP2	OTVU4G07	moderate	Biomarker	[435]
GRK6	OT4LZTP9	moderate	Biomarker	[436]
GSDMD	OTH39BKI	moderate	Biomarker	[437]
HDLBP	OTKDEEYX	moderate	Biomarker	[416]
HEBP1	OTR9MPDX	moderate	Biomarker	[416]
HECTD3	OTTGP4OK	moderate	Biomarker	[438]
HJV	OT4235J2	moderate	Biomarker	[439]
IFNE	OTXO5MHZ	moderate	Biomarker	[440]
ILF2	OTWWVM9X	moderate	Biomarker	[441]
ILF3	OTKMZ5K5	moderate	Altered Expression	[441]
IRF7	OTC1A2PQ	moderate	Biomarker	[442]
IRGM	OTKD3O5Z	moderate	Biomarker	[443]
ITM2A	OT590V63	moderate	Genetic Variation	[444]
KAT8	OT5LPQTR	moderate	Biomarker	[445]
KLRD1	OTMYLOV4	moderate	Biomarker	[324]
LECT2	OTSFZ9JD	moderate	Biomarker	[446]
MLKL	OTDSLC81	moderate	Biomarker	[447]
MPEG1	OT7DAO0F	moderate	Altered Expression	[448]
MRTFA	OTCVXASM	moderate	Genetic Variation	[449]
NCAPD3	OTOZY2UL	moderate	Altered Expression	[450]
NECTIN1	OTTE5ZR6	moderate	Genetic Variation	[415]
NFATC3	OTYOORME	moderate	Altered Expression	[441]
NGB	OTW0SIUY	moderate	Altered Expression	[451]
NR2E3	OTO3GBHQ	moderate	Biomarker	[452]
PADI1	OT13WAQX	moderate	Genetic Variation	[453]
PDIA2	OTC2WMXS	moderate	Genetic Variation	[453]
PIEZO1	OTBG1FU4	moderate	Biomarker	[454]
PLA2G10	OTRZ2L5A	moderate	Biomarker	[455]
PLAAT1	OTM3M6P4	moderate	Altered Expression	[413]
POPDC2	OTDAZSY5	moderate	Biomarker	[424]
POTEM	OT7L2HGH	moderate	Altered Expression	[413]
POU2F3	OTIOOJWD	moderate	Biomarker	[456]
PTMA	OT2W4T1M	moderate	Altered Expression	[457]
PYDC2	OTRWKIYY	moderate	Biomarker	[424]
RASIP1	OTCRY2AN	moderate	Biomarker	[458]
RSAD2	OTCA9WCM	moderate	Altered Expression	[459]
RTL10	OTHGB81W	moderate	Biomarker	[418]
S100A7	OTJFVJRF	moderate	Altered Expression	[460]
SAA2	OTYAVJWG	moderate	Genetic Variation	[461]
SCNN1B	OT61QQTL	moderate	Biomarker	[462]
SFTPB	OTOHS07E	moderate	Biomarker	[463]
SLBP	OTVYYQRT	moderate	Biomarker	[416]
SNX10	OT05B7BT	moderate	Biomarker	[464]
STAM2	OT9OBWPH	moderate	Biomarker	[416]
STX6	OTC5F5M6	moderate	Biomarker	[465]
TAB1	OTPM6F85	moderate	Biomarker	[466]
TAS2R38	OTX5MM36	moderate	Genetic Variation	[467]
TLR10	OTQ1KVJO	moderate	Biomarker	[468]
TRIM33	OT0KS4J7	moderate	Biomarker	[469]
ARHGEF28	OT3F32IU	Strong	Biomarker	[370]
ATG16L1	OTEOYC5D	Strong	Biomarker	[470]
CD1B	OT4D5EG7	Strong	Genetic Variation	[471]
CD1D	OT3ROU4J	Strong	Biomarker	[472]
CD200R1	OT65Q9M6	Strong	Biomarker	[473]
CLEC7A	OTRTBH27	Strong	Biomarker	[474]
CPD	OT2CS64Y	Strong	Genetic Variation	[475]
CYRIB	OTLRN4L1	Strong	Biomarker	[476]
DEFB103B	OT8RWY64	Strong	Biomarker	[477]
DNASE2	OT6RC1BL	Strong	Genetic Variation	[478]
DOCK8	OTNQLL21	Strong	Altered Expression	[479]
EDA	OTAKS5WS	Strong	Biomarker	[480]
FADD	OTV7GFHH	Strong	Altered Expression	[481]
FCGR2C	OTNLMNYB	Strong	Genetic Variation	[482]
FEV	OTYEC4IR	Strong	Genetic Variation	[483]
GCA	OTAJ7ZHG	Strong	Altered Expression	[484]
HRG	OTPLUFOG	Strong	Biomarker	[485]
IFNA1	OTPMKY0L	Strong	Biomarker	[486]
IKBKG	OTNWJWSD	Strong	Biomarker	[487]
IL27	OTIS3OF8	Strong	Altered Expression	[488]
IRAK2	OT6Y1QZN	Strong	Biomarker	[489]
ITIH4	OT460OO1	Strong	Biomarker	[490]
LEAP2	OTUOPIS5	Strong	Altered Expression	[491]
MASP1	OTWWCNZP	Strong	Biomarker	[492]
MICU1	OTS7N0LE	Strong	Altered Expression	[493]
NAIP	OTLA925F	Strong	Biomarker	[494]
NLRC4	OTAIA3NA	Strong	Biomarker	[495]
OR10A4	OTYYB8SY	Strong	Biomarker	[496]
P4HB	OTTYNYPF	Strong	Genetic Variation	[453]
PARP9	OT7K4494	Strong	Biomarker	[339]
PGLYRP1	OTBTPR2T	Strong	Altered Expression	[497]
PGLYRP2	OTF8319A	Strong	Altered Expression	[498]
PI3	OT47MTC3	Strong	Altered Expression	[499]
PIGR	OT6GLSUL	Strong	Genetic Variation	[500]
PROK1	OT8S7RUG	Strong	Biomarker	[501]
STING1	OTDAP4G0	Strong	Biomarker	[502]
TFEB	OTJUJJQY	Strong	Biomarker	[503]
TMEM59	OTX4EKES	Strong	Biomarker	[504]
MORN2	OTL98XZO	Definitive	Biomarker	[505]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Drug information of Amdinocillin, 2008. eduDrugs.
• [3] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [4] Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
• [5] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061936.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7345).
• [7] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [8] Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92.
• [9] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050520.
• [10] Drug information of Benzylpenicilloyl Polylysine, 2008. eduDrugs.
• [11] The role of natural product chemistry in drug discovery. J Nat Prod. 2004 Dec;67(12):2141-53.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001134)
• [13] Drug information of Candicidin, 2008. eduDrugs.
• [14] Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
• [15] Drug information of Cefacetrile, 2008. eduDrugs.
• [16] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062206.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4831).
• [18] Cefalotin - FDA approved drug information (drug label) from DailyMed.
• [19] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065244.
• [20] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050637.
• [21] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064200.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4830).
• [23] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326).
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4832).
• [25] Drug information of Cephaloglycin, 2008. eduDrugs.
• [26] The Cephalosporin Antimicrobial Agents: A Comprehensive Review. J Vet Pharmacol Ther 11 (1):1-32. 1988.
• [27] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019822.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5166).
• [29] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065063.
• [30] Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5.
• [31] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061454.
• [32] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4817).
• [33] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [34] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [35] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062286.
• [36] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
• [37] Drug information of Fleroxacin, Health Canada, 2007.
• [38] Drug information of Flucloxacillin, 2008. eduDrugs.
• [39] Drug information of Framycetin, 2008. eduDrugs.
• [40] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2427).
• [41] Drug information of Gramicidin D, 2008. eduDrugs.
• [42] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020695.
• [43] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017452.
• [44] Drug information of Josamycin, 2008. eduDrugs.
• [45] Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
• [46] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 200222.
• [47] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020013.
• [48] Drug information of Lymecycline, 2008. eduDrugs.
• [49] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 065094.
• [50] Drug information of Methacycline, 2008. eduDrugs.
• [51] Drug information of Meticillin, 2008. eduDrugs.
• [52] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [53] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013595)
• [54] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074690.
• [55] ClinicalTrials.gov (NCT00865280) Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI). U.S. National Institutes of Health.
• [56] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 061490.
• [57] D-Ala-D-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6480-3.
• [58] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 060634.
• [59] ClinicalTrials.gov (NCT02090764) Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo. U.S. National Institutes of Health.
• [60] ClinicalTrials.gov (NCT00363688) Treating Patients With a History of Non-Life Threatening Allergic Reaction to Penicillin With Penicillin. U.S. National Institutes of Health.
• [61] Zosyn (piperacillin/tazobactam) reformulation: Expanded compatibility and coadministration with lactated Ringer's solutions and selected aminoglycosides. Ther Clin Risk Manag. 2008 Apr;4(2):303-14.
• [62] Drug information of Pivampicillin, 2008. eduDrugs.
• [63] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [64] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7290).
• [65] ClinicalTrials.gov (NCT01654939) Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease. U.S. National Institutes of Health.
• [66] Drug information of Rosoxacin, 2008. eduDrugs.
• [67] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4126).
• [68] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020677.
• [69] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050347.
• [70] Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22.
• [71] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080123.
• [72] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080123.
• [73] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 088718.
• [74] Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr Opin Microbiol. 2005 Oct;8(5):510-7.
• [75] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2616).
• [76] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050497.
• [77] 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
• [78] Triamcinolone FDA Label
• [79] Drug Information of Dihydrotachysterol from nextbio research in illumina. 2015.
• [80] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050762.
• [81] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [82] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009829)
• [83] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009417)
• [84] ClinicalTrials.gov (NCT02257918) Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea. U.S. National Institutes of Health.
• [85] Usefulness of 7 day therapy with cefluprenam in the management of respiratory tract infections. Kansenshogaku Zasshi. 1997 Aug;71(8):770-87.
• [86] ClinicalTrials.gov (NCT00004408) Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease. U.S. National Institutes of Health.
• [87] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 700243326)
• [88] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012480)
• [89] ClinicalTrials.gov (NCT01251133) Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study. U.S. National Institutes of Health.
• [90] ClinicalTrials.gov (NCT00002445) Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients. U.S. National Institutes of Health.
• [91] ClinicalTrials.gov (NCT00231153) Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters. U.S. National Institutes of Health.
• [92] Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect Ther. 2006 Dec;4(6):939-45.
• [93] ClinicalTrials.gov (NCT00251849) PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients. U.S. National Institutes of Health.
• [94] Clinical pipeline report, company report or official report of BELLUS Health Inc.
• [95] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [96] Final HIV Results of Ushercell Trials Presented at IAS Conference in Sydney. Phase III Trials of Cellulose Sulfate Microbicide for HIV Prevention Closed. Arlington, VA, January 31, 2007.
• [97] ClinicalTrials.gov (NCT00635622) Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis. U.S. National Institutes of Health.
• [98] Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol. 2012 Feb 22;2:16.
• [99] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038764)
• [100] Clinical pipeline report, company report or official report of AiCuris.
• [101] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037513)
• [102] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013296)
• [103] ClinicalTrials.gov (NCT01119105) Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI). U.S. National Institutes of Health.
• [104] Clinical pipeline report, company report or official report of Boston Pharmaceuticals.
• [105] ClinicalTrials.gov (NCT01593761) Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus. U.S. National Institutes of Health.
• [106] Clinical pipeline report, company report or official report of Eisai.
• [107] ClinicalTrials.gov (NCT00270517) Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia. U.S. National Institutes of Health.
• [108] Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36.
• [109] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002282)
• [110] ClinicalTrials.gov (NCT01223222) A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar (LTX-109) on Uncomplicated, Gram-positive, Skin Infection. U.S. National Institutes of Health.
• [111] Clinical pipeline report, company report or official report of Merck (May 7, 2015).
• [112] Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis - a phase II pilot study. Ophthalmologica. 2000;214(2):111-4.
• [113] Clinical pipeline report, company report or official report of Nucryst Pharmaceuticals.
• [114] ClinicalTrials.gov (NCT02096328) Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia. U.S. National Institutes of Health.
• [115] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7997).
• [116] ClinicalTrials.gov (NCT00797108) A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization. U.S. National Institutes of Health.
• [117] ClinicalTrials.gov (NCT00198289) Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs. U.S. National Institutes of Health.
• [118] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035884)
• [119] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016734)
• [120] Clinical pipeline report, company report or official report of Emergent BioSolutions.
• [121] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [122] ClinicalTrials.gov (NCT00509847) A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis. U.S. National Institutes of Health.
• [123] ClinicalTrials.gov (NCT01643941) Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years. U.S. National Institutes of Health.
• [124] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037565)
• [125] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037454)
• [126] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032341)
• [127] Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503.
• [128] Pharmacokinetics and safety of ascending single doses of DZ-2640, a new oral carbapenem antibiotic, administered to healthy Japanese subjects. Antimicrob Agents Chemother. 2000 Mar;44(3):578-82.
• [129] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028928)
• [130] ClinicalTrials.gov (NCT02255968) Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788. U.S. National Institutes of Health.
• [131] ClinicalTrials.gov (NCT00492271) First Time in Man Trial for Friulimicin B. U.S. National Institutes of Health.
• [132] GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol. 2000 Dec 15;304(5):995-1005.
• [133] In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A).. Antimicrob Agents Chemother. 1993 April; 37(4): 741-745.
• [134] ClinicalTrials.gov (NCT00463697) A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients. U.S. National Institutes of Health.
• [135] ClinicalTrials.gov (NCT01904318) A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer. U.S. National Institutes of Health.
• [136] A Screening Room for Cerebral Malaria Drugs. Sci Transl Med 4, 135ra64 (2012).
• [137] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011609)
• [138] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027139)
• [139] ClinicalTrials.gov (NCT02134834) A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595. U.S. National Institutes of Health.
• [140] Isoprene formation in Bacillus subtilis: a barometer of central carbon assimilation in a bioreactor. Biotechnol Prog. 2002 Sep-Oct;18(5):1109-15.
• [141] ClinicalTrials.gov (NCT05072444) A Phase 1, Randomized, Double-Blind, Single-Dose, Drug-Drug Interaction Study to Determine the Impact of Co-administration of QPX7728 on the Pharmacokinetics of QPX2014 in Healthy Adult Subjects. U.S.National Institutes of Health.
• [142] Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52.
• [143] Clinical pipeline report, company report or official report of Roche
• [144] Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother. 2012 Nov 1;8(11):1585-94.
• [145] ClinicalTrials.gov (NCT02500914) SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma.
• [146] ClinicalTrials.gov (NCT04763759) A Phase 1, Blinded, Single Ascending Dose Study to Evaluate Safety, Pharmacokinetics, and Activity of TRL1068 in Subjects With Prosthetic Joint Infection of the Knee or Hip, Undergoing Primary Two Stage Exchange Arthroplasty. U.S.National Institutes of Health.
• [147] ClinicalTrials.gov (NCT01265745) Dose Escalation Study of Valortim (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects. U.S. National Institutes of Health.
• [148] ClinicalTrials.gov (NCT02955459) VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers. U.S. National Institutes of Health.
• [149] Clinical pipeline report, company report or official report of NanoBio Corp.
• [150] Effect of WF11605, a novel LTB4 antagonist on galactosamine-induced hepatitis in rats. Ensho. ISSN:0389-4290, VOL.12, NO.4, PAGE.373-377, (1992).
• [151] ClinicalTrials.gov (NCT04802863) A Phase 1, Open-label Study to Evaluate the Safety and Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects. U.S.National Institutes of Health.
• [152] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [153] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1465).
• [154] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000542)
• [155] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002768)
• [156] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000507)
• [157] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000546)
• [158] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002619)
• [159] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000482)
• [160] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002596)
• [161] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005626)
• [162] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002696)
• [163] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015146)
• [164] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006301)
• [165] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002101)
• [166] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016806)
• [167] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004047)
• [168] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001782)
• [169] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002693)
• [170] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003016)
• [171] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002102)
• [172] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004010)
• [173] Pharmacokinetic and pharmacodynamic profiles of danofloxacin administered by two dosing regimens in calves infected with Mannheimia (Pasteurella) haemolytica. Antimicrob Agents Chemother. 2002 Sep;46(9):3013-9.
• [174] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019670)
• [175] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002322)
• [176] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004009)
• [177] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007881)
• [178] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000467)
• [179] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011023)
• [180] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000529)
• [181] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011696)
• [182] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002695)
• [183] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014654)
• [184] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001897)
• [185] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001510)
• [186] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005339)
• [187] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017594)
• [188] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029693)
• [189] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003956)
• [190] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002807)
• [191] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001898)
• [192] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024195)
• [193] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016728)
• [194] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032713)
• [195] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006219)
• [196] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002052)
• [197] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002788)
• [198] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003960)
• [199] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005932)
• [200] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007635)
• [201] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002851)
• [202] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003310)
• [203] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027355)
• [204] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014914)
• [205] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012748)
• [206] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009332)
• [207] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011406)
• [208] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001614)
• [209] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028999)
• [210] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016730)
• [211] Clinical pipeline report, company report or official report of Takeda.
• [212] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015826)
• [213] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021291)
• [214] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800042180)
• [215] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034589)
• [216] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014760)
• [217] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017411)
• [218] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016773)
• [219] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019836)
• [220] Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
• [221] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017450)
• [222] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016810)
• [223] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016809)
• [224] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001978)
• [225] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003751)
• [226] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018239)
• [227] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020451)
• [228] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007738)
• [229] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000460)
• [230] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000465)
• [231] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005424)
• [232] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001128)
• [233] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016793)
• [234] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027165)
• [235] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005427)
• [236] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013262)
• [237] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004648)
• [238] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002821)
• [239] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003590)
• [240] Cephalosporin antibiotics. II. Synthesis and biological properties of CS-461 and related compounds. J Antibiot (Tokyo). 1991 Aug;44(8):864-9.
• [241] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000500)
• [242] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010813)
• [243] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002763)
• [244] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002670)
• [245] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013554)
• [246] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012749)
• [247] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011889)
• [248] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000463)
• [249] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012632)
• [250] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004667)
• [251] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006998)
• [252] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010886)
• [253] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006322)
• [254] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006309)
• [255] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018199)
• [256] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010218)
• [257] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019686)
• [258] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017539)
• [259] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000523)
• [260] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006715)
• [261] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015333)
• [262] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003745)
• [263] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018127)
• [264] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000528)
• [265] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001133)
• [266] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000531)
• [267] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003874)
• [268] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003611)
• [269] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003834)
• [270] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002781)
• [271] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003623)
• [272] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001507)
• [273] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004710)
• [274] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004644)
• [275] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006319)
• [276] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006850)
• [277] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004684)
• [278] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008139)
• [279] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007655)
• [280] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003642)
• [281] Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob Agents Chemother. 2002 Jun;46(6):1880-6.
• [282] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000545)
• [283] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000537)
• [284] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003943)
• [285] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005694)
• [286] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008847)
• [287] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002805)
• [288] In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother. 2010 Aug;54(8):3478-80.
• [289] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155).
• [290] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [291] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019101)
• [292] Using Arden Syntax Medical Logic Modules to reduce overutilization of laboratory tests for detection of bacterial infections-Success or failure?.Artif Intell Med. 2018 Nov;92:43-50. doi: 10.1016/j.artmed.2015.09.005. Epub 2015 Sep 25.
• [293] Caspase-11-dependent pyroptosis of lung epithelial cells protects from melioidosis while caspase-1 mediates macrophage pyroptosis and production of IL-18.PLoS Pathog. 2018 May 23;14(5):e1007105. doi: 10.1371/journal.ppat.1007105. eCollection 2018 May.
• [294] Changes in Chemokines and Chemokine Receptors Expression in a Mouse Model of Alzheimer's Disease.Int J Biol Sci. 2019 Jan 1;15(2):453-463. doi: 10.7150/ijbs.26703. eCollection 2019.
• [295] Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471).Curr Med Chem. 2020;27(25):4165-4180. doi: 10.2174/0929867326666191001130342.
• [296] Neutrophil elastase as a biomarker for bacterial infection in COPD.Respir Res. 2019 Jul 30;20(1):170. doi: 10.1186/s12931-019-1145-4.
• [297] Fas-associated factor 1 mediates NADPH oxidase-induced reactive oxygen species production and proinflammatory responses in macrophages against Listeria infection.PLoS Pathog. 2019 Aug 14;15(8):e1008004. doi: 10.1371/journal.ppat.1008004. eCollection 2019 Aug.
• [298] Gpr174-deficient regulatory T cells decrease cytokine storm in septic mice.Cell Death Dis. 2019 Mar 8;10(3):233. doi: 10.1038/s41419-019-1462-z.
• [299] Cigarette smoke extract modulates Pseudomonas aeruginosa bacterial load via USP25/HDAC11 axis in lung epithelial cells.Am J Physiol Lung Cell Mol Physiol. 2020 Feb 1;318(2):L252-L263. doi: 10.1152/ajplung.00142.2019. Epub 2019 Nov 20.
• [300] Immunologic environment influences macrophage response to Porphyromonas gingivalis.Mol Oral Microbiol. 2017 Jun;32(3):250-261. doi: 10.1111/omi.12168. Epub 2016 Aug 26.
• [301] Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease.Respirology. 2020 Jan;25(1):53-63. doi: 10.1111/resp.13722. Epub 2019 Oct 30.
• [302] Complete Genome Sequence of Streptomyces olivoreticuli ATCC 31159 Which can Produce Anticancer Bestatin and Show Diverse Secondary Metabolic Potentials.Curr Microbiol. 2019 Mar;76(3):370-375. doi: 10.1007/s00284-019-01638-3. Epub 2019 Jan 31.
• [303] Acid Sphingomyelinase-Ceramide System in Bacterial Infections.Cell Physiol Biochem. 2019;52(2):280-301. doi: 10.33594/000000021. Epub 2019 Feb 28.
• [304] Plasma thrombopoietin levels as additional tool in clinical management of thrombocytopenic neonates.Platelets. 2020;31(1):62-67. doi: 10.1080/09537104.2019.1572877. Epub 2019 Feb 13.
• [305] BAFF augments IgA2 and IL-10 production by TLR7/8 stimulated total peripheral blood Bcells.Eur J Immunol. 2018 Feb;48(2):283-292. doi: 10.1002/eji.201646861. Epub 2017 Oct 11.
• [306] De Novo Endotoxin-Induced Production of Antibodies against the Bile Salt Export Pump Associated with Bacterial Infection following Major Hepatectomy.Biomed Res Int. 2018 Apr 23;2018:6197152. doi: 10.1155/2018/6197152. eCollection 2018.
• [307] Identification of single nucleotide polymorphisms in hematopoietic cell transplant patients affecting early recognition of, and response to, endotoxin.Innate Immun. 2014 Oct;20(7):697-711. doi: 10.1177/1753425913505122. Epub 2013 Oct 9.
• [308] CASP4/caspase-11 promotes autophagosome formation in response to bacterial infection.Autophagy. 2018;14(11):1928-1942. doi: 10.1080/15548627.2018.1491494. Epub 2018 Aug 31.
• [309] Sensing of cytosolic LPS through caspy2 pyrin domain mediates noncanonical inflammasome activation in zebrafish.Nat Commun. 2018 Aug 3;9(1):3052. doi: 10.1038/s41467-018-04984-1.
• [310] Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model.Front Immunol. 2018 May 31;9:1204. doi: 10.3389/fimmu.2018.01204. eCollection 2018.
• [311] Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease.Inflamm Bowel Dis. 2012 May;18(5):913-24. doi: 10.1002/ibd.21899. Epub 2011 Oct 12.
• [312] Topical nicotinic receptor activation improves wound bacterial infection outcomes and TLR2-mediated inflammation in diabetic mouse wounds.Wound Repair Regen. 2018 Nov;26(6):403-412. doi: 10.1111/wrr.12674. Epub 2018 Oct 24.
• [313] Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.Acta Trop. 2016 Dec;164:329-336. doi: 10.1016/j.actatropica.2016.09.008. Epub 2016 Sep 17.
• [314] Genome-wide identification of hsp40 genes in channel catfish and their regulated expression after bacterial infection.PLoS One. 2014 Dec 26;9(12):e115752. doi: 10.1371/journal.pone.0115752. eCollection 2014.
• [315] The GCN2-ATF4 Signaling Pathway Induces 4E-BP to Bias Translation and Boost Antimicrobial Peptide Synthesis in Response to Bacterial Infection.Cell Rep. 2017 Nov 21;21(8):2039-2047. doi: 10.1016/j.celrep.2017.10.096.
• [316] Deletion of glutaredoxin promotes oxidative tolerance and intracellular infection in Listeria monocytogenes.Virulence. 2019 Dec;10(1):910-924. doi: 10.1080/21505594.2019.1685640.
• [317] BacCapSeq: a Platform for Diagnosis and Characterization of Bacterial Infections.mBio. 2018 Oct 23;9(5):e02007-18. doi: 10.1128/mBio.02007-18.
• [318] Anti-microbial Functions of Group 3 Innate Lymphoid Cells in Gut-Associated Lymphoid Tissues Are Regulated by G-Protein-Coupled Receptor 183.Cell Rep. 2018 Jun 26;23(13):3750-3758. doi: 10.1016/j.celrep.2018.05.099.
• [319] Phylogeny and expression modulation of interleukin 1 receptors in grass carp (Ctenopharyngodon idella).Dev Comp Immunol. 2019 Oct;99:103401. doi: 10.1016/j.dci.2019.103401. Epub 2019 May 27.
• [320] A novel mouse model of conditional IRAK-M deficiency in myeloid cells: application in lung Pseudomonas aeruginosa infection.Innate Immun. 2017 Feb;23(2):206-215. doi: 10.1177/1753425916684202. Epub 2016 Dec 18.
• [321] Shedding new light on vasculitis: how the LAMP story unfolded.J Nephrol. 2012 Sep-Oct;25(5):636-43. doi: 10.5301/jn.5000107.
• [322] Cation-dependent mannose-6-phosphate receptor functions as a pattern recognition receptor in anti-bacterial immunity of Marsupenaeus japonicus.Dev Comp Immunol. 2018 Dec;89:122-130. doi: 10.1016/j.dci.2018.08.011. Epub 2018 Aug 16.
• [323] A Connective Tissue Mast-Cell-Specific Receptor Detects Bacterial Quorum-Sensing Molecules and Mediates Antibacterial Immunity.Cell Host Microbe. 2019 Jul 10;26(1):114-122.e8. doi: 10.1016/j.chom.2019.06.003. Epub 2019 Jul 2.
• [324] NCR1-deficiency diminishes the generation of protective murine cytomegalovirus antibodies by limiting follicular helper T-cell maturation.Eur J Immunol. 2017 Sep;47(9):1443-1456. doi: 10.1002/eji.201646763. Epub 2017 Jul 21.
• [325] Comparison of O-polysaccharide and hemolysin co-regulated protein as target antigens for serodiagnosis of melioidosis.PLoS Negl Trop Dis. 2017 Mar 30;11(3):e0005499. doi: 10.1371/journal.pntd.0005499. eCollection 2017 Mar.
• [326] MPEG-PCL Copolymeric Micelles for Encapsulation of Azithromycin.AAPS PharmSciTech. 2018 Jul;19(5):2041-2047. doi: 10.1208/s12249-018-1009-0. Epub 2018 Apr 19.
• [327] Protective effects of seaweed supplemented diet on antioxidant and immune responses in European seabass (Dicentrarchus labrax) subjected to bacterial infection.Sci Rep. 2019 Nov 6;9(1):16134. doi: 10.1038/s41598-019-52693-6.
• [328] The multifaceted role of the E3 ubiquitin ligase HOIL-1: beyond linear ubiquitination.Immunol Rev. 2015 Jul;266(1):208-21. doi: 10.1111/imr.12307.
• [329] SGLT1 Deficiency Turns Listeria Infection into a Lethal Disease in Mice.Cell Physiol Biochem. 2017;42(4):1358-1365. doi: 10.1159/000479197. Epub 2017 Jul 14.
• [330] Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation.Cell. 2017 Nov 16;171(5):1057-1071.e11. doi: 10.1016/j.cell.2017.09.029. Epub 2017 Oct 12.
• [331] Downregulated NDR1 protein kinase inhibits innate immune response by initiating an miR146a-STAT1 feedback loop.Nat Commun. 2018 Jul 17;9(1):2789. doi: 10.1038/s41467-018-05176-7.
• [332] ER-localized Hrd1 ubiquitinates and inactivates Usp15 to promote TLR4-induced inflammation during bacterial infection.Nat Microbiol. 2019 Dec;4(12):2331-2346. doi: 10.1038/s41564-019-0542-2.
• [333] An Essential Role for TAGLN2 in Phagocytosis of Lipopolysaccharide-activated Macrophages.Sci Rep. 2017 Aug 18;7(1):8731. doi: 10.1038/s41598-017-09144-x.
• [334] Toll-like receptor 6 V327M polymorphism is associated with an increased risk of Klebsiella pneumoniae infection.Pediatr Infect Dis J. 2014 Nov;33(11):e310-5. doi: 10.1097/INF.0000000000000395.
• [335] Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12952-12957. doi: 10.1073/pnas.1821552116. Epub 2019 Jun 12.
• [336] Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies.J Clin Invest. 1976 Jun;57(6):1626-34. doi: 10.1172/JCI108433.
• [337] PU.1 and epigenetic signals modulate 1,25-dihydroxyvitamin D(3) and C/EBP regulation of the human cathelicidin antimicrobial peptide gene in lung epithelial cells.J Cell Physiol. 2019 Jul;234(7):10345-10359. doi: 10.1002/jcp.27702. Epub 2018 Nov 1.
• [338] TLR4 and TLR21 expression, MIF, IFN-, MD-2, CD14 activation, and sIgA production in chickens administered with EFAL41 strain challenged with Campylobacter jejuni.Folia Microbiol (Praha). 2017 Mar;62(2):89-97. doi: 10.1007/s12223-016-0475-6. Epub 2016 Oct 3.
• [339] Interleukin-1 is associated with inflammation and structural lung disease in young children with cystic fibrosis.J Cyst Fibros. 2018 Nov;17(6):715-722. doi: 10.1016/j.jcf.2018.05.006. Epub 2018 Jun 6.
• [340] Classical and Non-classical Presentations of Complement Factor I Deficiency: Two Contrasting Cases Diagnosed via Genetic and Genomic Methods.Front Immunol. 2019 Jun 7;10:1150. doi: 10.3389/fimmu.2019.01150. eCollection 2019.
• [341] The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.Expert Opin Ther Targets. 2018 Aug;22(8):687-701. doi: 10.1080/14728222.2018.1501361. Epub 2018 Jul 26.
• [342] Induction of human -defensin-2 in pulmonary epithelial cells by Legionella pneumophila: involvement of TLR2 and TLR5, p38 MAPK, JNK, NF-B, and AP-1.Am J Physiol Lung Cell Mol Physiol. 2010 May;298(5):L687-95. doi: 10.1152/ajplung.00365.2009. Epub 2010 Feb 12.
• [343] Prostanoid-dependent spontaneous pain and PAR(2)-dependent mechanical allodynia following oral mucosal trauma: involvement of TRPV1, TRPA1 and TRPV4.Mol Pain. 2017 Jan;13:1744806917704138. doi: 10.1177/1744806917704138.
• [344] Cigarette smoke inhibits LPS-induced FABP5 expression by preventing c-Jun binding to the FABP5 promoter.PLoS One. 2017 May 18;12(5):e0178021. doi: 10.1371/journal.pone.0178021. eCollection 2017.
• [345] Accuracy of CD64 expression on neutrophils and monocytes in bacterial infection diagnosis at pediatric intensive care admission.Eur J Clin Microbiol Infect Dis. 2019 Jun;38(6):1079-1085. doi: 10.1007/s10096-019-03497-z. Epub 2019 Feb 2.
• [346] Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A.J Immunol. 2009 Dec 15;183(12):8216-24. doi: 10.4049/jimmunol.0902550.
• [347] Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003 Jul 11;278(28):25481-9.
• [348] Epidermal hepcidin is required for neutrophil response to bacterial infection.J Clin Invest. 2020 Jan 2;130(1):329-334. doi: 10.1172/JCI126645.
• [349] Interleukin-17D Aggravates Sepsis by Inhibiting Macrophage Phagocytosis.Crit Care Med. 2020 Jan;48(1):e58-e65. doi: 10.1097/CCM.0000000000004070.
• [350] Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.J Hepatol. 2020 Apr;72(4):736-745. doi: 10.1016/j.jhep.2019.11.013. Epub 2019 Nov 29.
• [351] Immunostimulatory activity of low-molecular-weight hyaluronan on dendritic cells stimulated with Aggregatibacter actinomycetemcomitans or Porphyromonas gingivalis.Clin Oral Investig. 2019 Apr;23(4):1887-1894. doi: 10.1007/s00784-018-2641-5. Epub 2018 Sep 17.
• [352] Interleukin-7 protects against bacterial respiratory infection by promoting IL-17A-producing innate T-cell response.Mucosal Immunol. 2020 Jan;13(1):128-139. doi: 10.1038/s41385-019-0212-y. Epub 2019 Oct 18.
• [353] IRF3 Inhibits Neutrophil Recruitment in Mice Infected with Pseudomonas aeruginosa.Inflammation. 2017 Jun;40(3):735-744. doi: 10.1007/s10753-017-0517-5.
• [354] ISG15 in Host Defense Against Candida albicans Infection in a Mouse Model of Fungal Keratitis.Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2948-2958. doi: 10.1167/iovs.17-21476.
• [355] Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1.Blood. 1985 Oct;66(4):882-90.
• [356] Efficiency of different fragment lengths of the ubiquitous chromatin opening element HNRPA2B1-CBX3 in driving human CD18 gene expression within self-inactivating lentiviral vectors for gene therapy applications.Gene. 2019 Aug 20;710:265-272. doi: 10.1016/j.gene.2019.06.016. Epub 2019 Jun 11.
• [357] NKG2D: A versatile player in the immune system.Immunol Lett. 2017 Sep;189:48-53. doi: 10.1016/j.imlet.2017.04.006. Epub 2017 Apr 13.
• [358] High serum lipopolysaccharide binding protein is associated with increased mortality in patients with decompensated cirrhosis.Liver Int. 2017 Apr;37(4):576-582. doi: 10.1111/liv.13264. Epub 2016 Oct 31.
• [359] Lipocalin-2 is dispensable in inflammation-induced sickness and depression-like behavior.Psychopharmacology (Berl). 2019 Oct;236(10):2975-2982. doi: 10.1007/s00213-019-05190-7. Epub 2019 Feb 26.
• [360] The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection.BMC Immunol. 2009 Oct 27;10:56. doi: 10.1186/1471-2172-10-56.
• [361] MD-2 as the target of curcumin in the inhibition of response to LPS.J Leukoc Biol. 2007 Oct;82(4):968-74. doi: 10.1189/jlb.1206727. Epub 2007 Jul 3.
• [362] Milk from transgenic goat expressing human lysozyme for recovery and treatment of gastrointestinal pathogens.Eur J Pharm Sci. 2018 Jan 15;112:79-86. doi: 10.1016/j.ejps.2017.11.005. Epub 2017 Nov 8.
• [363] MPB, a novel berberine derivative, enhances lysosomal and bactericidal properties via TGF--activated kinase 1-dependent activation of the transcription factor EB.FASEB J. 2019 Jan;33(1):1468-1481. doi: 10.1096/fj.201801198R. Epub 2018 Aug 30.
• [364] Molecular characterization, expression patterns, and functional analysis of toll-interacting protein (Tollip) in Japanese eel Anguilla japonica.Fish Shellfish Immunol. 2019 Jul;90:52-64. doi: 10.1016/j.fsi.2019.04.053. Epub 2019 Apr 20.
• [365] NLRC5 deficiency does not influence cytokine induction by virus and bacteria infections.J Immunol. 2011 Jan 15;186(2):994-1000. doi: 10.4049/jimmunol.1002094. Epub 2010 Dec 8.
• [366] Activation of the Endoplasmic Reticulum Stress Response Impacts the NOD1 Signaling Pathway.Infect Immun. 2019 Jul 23;87(8):e00826-18. doi: 10.1128/IAI.00826-18. Print 2019 Aug.
• [367] Common NOD2 Risk Variants as Major Susceptibility Factors for Bacterial Infections in Compensated Cirrhosis.Clin Transl Gastroenterol. 2019 Jan;10(1):e00002. doi: 10.14309/ctg.0000000000000002.
• [368] Anti-PF4/heparin antibodies are increased in hospitalized patients with bacterial sepsis.Thromb Res. 2018 Nov;171:111-113. doi: 10.1016/j.thromres.2018.09.060. Epub 2018 Sep 27.
• [369] Antibacterial, antifungal and anticoagulant activities of chicken PLA2 group V expressed in Pichia pastoris.Int J Biol Macromol. 2018 Mar;108:127-134. doi: 10.1016/j.ijbiomac.2017.11.045. Epub 2017 Nov 10.
• [370] Histone H2A cooperates with RIP2 to induce the expression of antibacterial genes and MHC related genes.Dev Comp Immunol. 2019 Dec;101:103455. doi: 10.1016/j.dci.2019.103455. Epub 2019 Jul 20.
• [371] Rapid Multiplexed Detection on Lateral-Flow Devices Using a Laser Direct-Write Technique.Biosensors (Basel). 2018 Oct 20;8(4):97. doi: 10.3390/bios8040097.
• [372] Discovery of (5-Phenylfuran-2-yl)methanamine Derivatives as New Human Sirtuin 2 Inhibitors.Molecules. 2019 Jul 26;24(15):2724. doi: 10.3390/molecules24152724.
• [373] A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection.Nat Commun. 2018 Jun 19;9(1):2308. doi: 10.1038/s41467-018-04579-w.
• [374] [PI3K-AKT network roles in infectious diseases].Kansenshogaku Zasshi. 2008 May;82(3):161-7. doi: 10.11150/kansenshogakuzasshi1970.82.161.
• [375] MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses.J Biol Chem. 2009 Sep 4;284(36):24192-203. doi: 10.1074/jbc.M109.023044. Epub 2009 Jul 10.
• [376] Association between TLR2 + 2477G/A polymorphism and bacterial meningitis: a meta-analysis.Epidemiol Infect. 2018 Apr;146(5):642-647. doi: 10.1017/S0950268818000298. Epub 2018 Feb 19.
• [377] Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection.Infect Immun. 2019 Nov 18;87(12):e00742-19. doi: 10.1128/IAI.00742-19. Print 2019 Dec.
• [378] Viruses and bacteria in bronchial samples from patients with primary hypogammaglobulinemia.Am J Respir Crit Care Med. 1999 Apr;159(4 Pt 1):1199-204. doi: 10.1164/ajrccm.159.4.9807067.
• [379] Kinases Mst1 and Mst2 positively regulate phagocytic induction of reactive oxygen species and bactericidal activity.Nat Immunol. 2015 Nov;16(11):1142-52. doi: 10.1038/ni.3268. Epub 2015 Sep 28.
• [380] Utility of neutrophil CD64 and serum TREM-1 in distinguishing bacterial infection from disease flare in SLE and ANCA-associated vasculitis.Clin Rheumatol. 2019 Apr;38(4):997-1005. doi: 10.1007/s10067-018-4334-5. Epub 2018 Nov 16.
• [381] Slc6a13 deficiency promotes Th17 responses during intestinal bacterial infection.Mucosal Immunol. 2019 Mar;12(2):531-544. doi: 10.1038/s41385-018-0111-7. Epub 2018 Dec 6.
• [382] Tonicity inversely modulates lipocalin-2 (Lcn2/24p3/NGAL) receptor (SLC22A17) and Lcn2 expression via Wnt/-catenin signaling in renal inner medullary collecting duct cells: implications for cell fate and bacterial infection.Cell Commun Signal. 2018 Nov 7;16(1):74. doi: 10.1186/s12964-018-0285-3.
• [383] Increased expression of ATP12A proton pump in cystic fibrosis airways.JCI Insight. 2018 Oct 18;3(20):e123616. doi: 10.1172/jci.insight.123616.
• [384] HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules. Bioorg Med Chem Lett. 2019 May 1; 29(9):1106-1112.
• [385] Released Tryptophanyl-tRNA Synthetase Stimulates Innate Immune Responses against Viral Infection.J Virol. 2019 Jan 4;93(2):e01291-18. doi: 10.1128/JVI.01291-18. Print 2019 Jan 15.
• [386] Myeloid cell-specific inositol polyphosphate-4-phosphatase type I knockout mice impair bacteria clearance in a murine peritonitis model.Innate Immun. 2016 Aug;22(6):444-51. doi: 10.1177/1753425916652714. Epub 2016 Jun 1.
• [387] Synthesis and investigations of ciprofloxacin loaded engineered selenium lipid nanocarriers for effective drug delivery system for preventing lung infections of interstitial lung disease.J Photochem Photobiol B. 2019 Aug;197:111510. doi: 10.1016/j.jphotobiol.2019.05.007. Epub 2019 May 23.
• [388] Spermine oxidase promotes bile canalicular lumen formation through acrolein production.Sci Rep. 2017 Nov 1;7(1):14841. doi: 10.1038/s41598-017-14929-1.
• [389] Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease.PLoS One. 2011 Mar 30;6(3):e16857. doi: 10.1371/journal.pone.0016857.
• [390] GLUT1-dependent glycolysis regulates exacerbation of fibrosis via AIM2 inflammasome activation.Thorax. 2020 Mar;75(3):227-236. doi: 10.1136/thoraxjnl-2019-213571. Epub 2019 Dec 10.
• [391] Regulation of ATG4B stability by RNF5 limits basal levels of autophagy and influences susceptibility to bacterial infection.PLoS Genet. 2012;8(10):e1003007. doi: 10.1371/journal.pgen.1003007. Epub 2012 Oct 18.
• [392] Identification of ATP synthase subunit as a new maternal factor capable of protecting zebrafish embryos from bacterial infection.FASEB J. 2019 Nov;33(11):12983-13001. doi: 10.1096/fj.201901290R. Epub 2019 Sep 13.
• [393] The macrophage-specific V-ATPase subunit ATP6V0D2 restricts inflammasome activation and bacterial infection by facilitating autophagosome-lysosome fusion.Autophagy. 2019 Jun;15(6):960-975. doi: 10.1080/15548627.2019.1569916. Epub 2019 Jan 29.
• [394] CCAAT/enhancer-binding protein facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner.Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9113-8. doi: 10.1073/pnas.1202641109. Epub 2012 May 21.
• [395] A qPCR expression assay of IFI44L gene differentiates viral from bacterial infections in febrile children.Sci Rep. 2019 Aug 13;9(1):11780. doi: 10.1038/s41598-019-48162-9.
• [396] Decreased Ficolin-3-mediated Complement Lectin Pathway Activation and Alternative Pathway Amplification During Bacterial Infections in Patients With Type 2 Diabetes Mellitus.Front Immunol. 2019 Mar 20;10:509. doi: 10.3389/fimmu.2019.00509. eCollection 2019.
• [397] IFN receptor down-regulation facilitates Legionella survival in alveolar macrophages.J Leukoc Biol. 2020 Feb;107(2):273-284. doi: 10.1002/JLB.4MA1019-152R. Epub 2019 Dec 2.
• [398] ITLN in diploid hybrid fish (Carassius auratus cuvieri Carassius auratus red var ? is involved in host defense against bacterial infection.Dev Comp Immunol. 2020 Feb;103:103520. doi: 10.1016/j.dci.2019.103520. Epub 2019 Oct 15.
• [399] LAMTOR2/LAMTOR1 complex is required for TAX1BP1-mediated xenophagy.Cell Microbiol. 2019 Apr;21(4):e12981. doi: 10.1111/cmi.12981. Epub 2019 Jan 21.
• [400] Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model.Sci Transl Med. 2011 Apr 13;3(78):78ra32. doi: 10.1126/scitranslmed.3002042.
• [401] Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction.Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158538. doi: 10.1016/j.bbalip.2019.158538. Epub 2019 Oct 31.
• [402] NLRP12 Attenuates Inflammatory Bone Loss in Experimental Apical Periodontitis.J Dent Res. 2019 Apr;98(4):476-484. doi: 10.1177/0022034518820289. Epub 2019 Jan 25.
• [403] A Novel Biomimetic Nanosponge Protects the Retina from the Enterococcus faecalis Cytolysin.mSphere. 2017 Nov 22;2(6):e00335-17. doi: 10.1128/mSphere.00335-17. eCollection 2017 Nov-Dec.
• [404] Pseudomonas aeruginosa GroEL Stimulates Production of PTX3 by Activating the NF-B Pathway and Simultaneously Downregulating MicroRNA-9.Infect Immun. 2017 Feb 23;85(3):e00935-16. doi: 10.1128/IAI.00935-16. Print 2017 Mar.
• [405] Rab20 is critical for bacterial lipoprotein tolerization-enhanced bactericidal activity in macrophages during bacterial infection.Sci China Life Sci. 2020 Mar;63(3):401-409. doi: 10.1007/s11427-019-9527-3. Epub 2019 May 31.
• [406] High mobility group box 1 enables bacterial lipids to trigger receptor-interacting protein kinase 3 (RIPK3)-mediated necroptosis and apoptosis in mice.J Biol Chem. 2019 May 31;294(22):8872-8884. doi: 10.1074/jbc.RA118.007040. Epub 2019 Apr 18.
• [407] Role of Syndecan-4 in the cellular invasion of Orientia tsutsugamushi.Microb Pathog. 2004 Apr;36(4):219-25. doi: 10.1016/j.micpath.2003.12.005.
• [408] Deciphering the Role of Intramolecular Networking in Cholic Acid-Peptide Conjugates on the Lipopolysaccharide Surface in Combating Gram-Negative Bacterial Infections.J Med Chem. 2019 Feb 28;62(4):1875-1886. doi: 10.1021/acs.jmedchem.8b01357. Epub 2019 Feb 11.
• [409] Tropism and molecular pathogenesis of canine distemper virus.Virol J. 2019 Mar 7;16(1):30. doi: 10.1186/s12985-019-1136-6.
• [410] A novel function for SNAP29 (synaptosomal-associated protein of 29 kDa) in mast cell phagocytosis.PLoS One. 2012;7(11):e49886. doi: 10.1371/journal.pone.0049886. Epub 2012 Nov 21.
• [411] Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat Genet. 2002 Nov;32(3):448-52. doi: 10.1038/ng1012. Epub 2002 Oct 21.
• [412] Senescence-accelerated mice (SAMP1/TA-1) treated repeatedly with lipopolysaccharide develop a condition that resembles hemophagocytic lymphohistiocytosis.Haematologica. 2019 Oct;104(10):1995-2005. doi: 10.3324/haematol.2018.209551. Epub 2019 Feb 28.
• [413] Phospholipase A activity of adenylate cyclase toxin mediates translocation of its adenylate cyclase domain.Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):E6784-E6793. doi: 10.1073/pnas.1701783114. Epub 2017 Jul 31.
• [414] Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose.Nature. 2018 Sep;561(7721):122-126. doi: 10.1038/s41586-018-0433-3. Epub 2018 Aug 15.
• [415] Functional polymorphisms of innate immunity receptors are not risk factors for the non-SBP type bacterial infections in cirrhosis.Liver Int. 2018 Jul;38(7):1242-1252. doi: 10.1111/liv.13664. Epub 2018 Jan 17.
• [416] Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis.J Intern Med. 2017 Jun;281(6):562-574. doi: 10.1111/joim.12604. Epub 2017 Mar 28.
• [417] A Batf3/Nlrp3/IL-18 Axis Promotes Natural Killer Cell IL-10 Production during Listeria monocytogenes Infection.Cell Rep. 2018 May 29;23(9):2582-2594. doi: 10.1016/j.celrep.2018.04.106.
• [418] Loss of BID Delays FASL-Induced Cell Death of Mouse Neutrophils and Aggravates DSS-Induced Weight Loss.Int J Mol Sci. 2018 Feb 28;19(3):684. doi: 10.3390/ijms19030684.
• [419] Identification of second arginine-glycine-aspartic acid motif of ovine vitronectin as the complement C9 binding site and its implication in bacterial infection.Microbiol Immunol. 2017 Feb;61(2):75-84. doi: 10.1111/1348-0421.12468.
• [420] Lipopolysaccharide-Induced CD300b Receptor Binding to Toll-like Receptor 4 Alters Signaling to Drive Cytokine Responses that Enhance Septic Shock.Immunity. 2016 Jun 21;44(6):1365-78. doi: 10.1016/j.immuni.2016.05.005. Epub 2016 May 31.
• [421] Neutralization of viral infectivity by zebrafish c-reactive protein isoforms.Mol Immunol. 2017 Nov;91:145-155. doi: 10.1016/j.molimm.2017.09.005. Epub 2017 Sep 12.
• [422] Enzymatic Preparation of 2'-5',3'-5'-Cyclic Dinucleotides, Their Binding Properties to Stimulator of Interferon Genes Adaptor Protein, and Structure/Activity Correlations.J Med Chem. 2019 Dec 12;62(23):10676-10690. doi: 10.1021/acs.jmedchem.9b01062. Epub 2019 Nov 27.
• [423] Salmonella infection upregulates the leaky protein claudin-2 in intestinal epithelial cells.PLoS One. 2013;8(3):e58606. doi: 10.1371/journal.pone.0058606. Epub 2013 Mar 11.
• [424] Pyrin-only protein 2 limits inflammation but improves protection against bacteria.Nat Commun. 2017 Jun 5;8:15564. doi: 10.1038/ncomms15564.
• [425] Expression and functional characterization of collection-K1 from Nile tilapia (Oreochromis niloticus) in host innate immune defense.Mol Immunol. 2018 Nov;103:21-34. doi: 10.1016/j.molimm.2018.08.012. Epub 2018 Sep 3.
• [426] Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis.Mol Med. 2013 Aug 28;19(1):263-75. doi: 10.2119/molmed.2013.00081.
• [427] Self-Assembling Myristoylated Human -Defensin 5 as a Next-Generation Nanobiotics Potentiates Therapeutic Efficacy in Bacterial Infection.ACS Nano. 2018 Jun 26;12(6):5284-5296. doi: 10.1021/acsnano.7b09109. Epub 2018 Jun 8.
• [428] Dock2 in the development of inflammation and cancer.Eur J Immunol. 2018 Jun;48(6):915-922. doi: 10.1002/eji.201747157. Epub 2018 Apr 11.
• [429] Dual-Specificity Phosphatase 12 Targets p38 MAP Kinase to Regulate Macrophage Response to Intracellular Bacterial Infection.Front Immunol. 2017 Oct 9;8:1259. doi: 10.3389/fimmu.2017.01259. eCollection 2017.
• [430] Dissemination of Trimethoprim-Sulfamethoxazole Drug Resistance Genes Associated with Class 1 and Class 2 Integrons Among Gram-Negative Bacteria from HIV Patients in South India.Microb Drug Resist. 2017 Jul;23(5):602-608. doi: 10.1089/mdr.2016.0034. Epub 2016 Nov 17.
• [431] Nucleolar fibrillarin is an evolutionarily conserved regulator of bacterial pathogen resistance.Nat Commun. 2018 Sep 6;9(1):3607. doi: 10.1038/s41467-018-06051-1.
• [432] Fc Receptor Promotes the Survival and Activation of Marginal Zone B Cells and Protects Mice against Bacterial Sepsis.Front Immunol. 2018 Feb 5;9:160. doi: 10.3389/fimmu.2018.00160. eCollection 2018.
• [433] Optimal T Cell Activation and B Cell Antibody Responses In Vivo Require the Interaction between Leukocyte Function-Associated Antigen-1 and Kindlin-3.J Immunol. 2015 Jul 1;195(1):105-15. doi: 10.4049/jimmunol.1402741. Epub 2015 May 18.
• [434] TLR Stimulation Dynamically Regulates Heme and Iron Export Gene Expression in Macrophages.J Immunol Res. 2016;2016:4039038. doi: 10.1155/2016/4039038. Epub 2016 Feb 24.
• [435] Brucella abortus Triggers a cGAS-Independent STING Pathway To Induce Host Protection That Involves Guanylate-Binding Proteins and Inflammasome Activation.J Immunol. 2018 Jan 15;200(2):607-622. doi: 10.4049/jimmunol.1700725. Epub 2017 Dec 4.
• [436] Role of G protein-coupled receptor kinase-6 in Escherichia coli lung infection model in mice.Physiol Genomics. 2017 Nov 1;49(11):682-689. doi: 10.1152/physiolgenomics.00066.2017. Epub 2017 Sep 22.
• [437] Ion Man: GSDMD Punches Pores to Knock Out cGAS.Immunity. 2018 Sep 18;49(3):379-381. doi: 10.1016/j.immuni.2018.08.026.
• [438] HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection.J Clin Invest. 2018 Aug 31;128(9):4148-4162. doi: 10.1172/JCI120406. Epub 2018 Jul 30.
• [439] Hemojuvelin regulates the innate immune response to peritoneal bacterial infection in mice.Cell Discov. 2017 Aug 15;3:17028. doi: 10.1038/celldisc.2017.28. eCollection 2017.
• [440] Interferon- protects the female reproductive tract from viral and bacterial infection.Science. 2013 Mar 1;339(6123):1088-92. doi: 10.1126/science.1233321.
• [441] Characterization of nuclear factor of activated T-cells-c3 (NFATc3) and gene expression of upstream-downstream signaling molecules in response to immunostimulants in Pacific red snapper cells.Dev Comp Immunol. 2018 Jan;78:149-159. doi: 10.1016/j.dci.2017.10.001. Epub 2017 Oct 3.
• [442] IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections.Sci Transl Med. 2016 Apr 27;8(336):336ra59. doi: 10.1126/scitranslmed.aaf1156.
• [443] Metabolic Alterations Contribute to Enhanced Inflammatory Cytokine Production in Irgm1-deficient Macrophages.J Biol Chem. 2017 Mar 17;292(11):4651-4662. doi: 10.1074/jbc.M116.770735. Epub 2017 Feb 1.
• [444] ITM2A Expands Evidence for Genetic and Environmental Interaction in Graves Disease Pathogenesis.J Clin Endocrinol Metab. 2017 Feb 1;102(2):652-660. doi: 10.1210/jc.2016-2625.
• [445] Porous Iron-Carboxylate Metal-Organic Framework: A Novel Bioplatform with Sustained Antibacterial Efficacy and Nontoxicity.ACS Appl Mater Interfaces. 2017 Jun 7;9(22):19248-19257. doi: 10.1021/acsami.7b04810. Epub 2017 May 30.
• [446] Characterization of the LECT2 gene and its protective effects against microbial infection via large lymphocytes in Lampetra japonica.Dev Comp Immunol. 2018 Feb;79:75-85. doi: 10.1016/j.dci.2017.09.018. Epub 2017 Oct 19.
• [447] Transcription modulation by CDK9 regulates inflammatory genes and RIPK3-MLKL-mediated necroptosis in periodontitis progression.Sci Rep. 2019 Nov 22;9(1):17369. doi: 10.1038/s41598-019-53910-y.
• [448] Inhibition of intracellular bacterial replication in fibroblasts is dependent on the perforin-like protein (perforin-2) encoded by macrophage-expressed gene 1.J Innate Immun. 2013;5(2):185-94. doi: 10.1159/000345249. Epub 2012 Dec 15.
• [449] Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1.Blood. 2015 Sep 24;126(13):1527-35. doi: 10.1182/blood-2014-12-611012. Epub 2015 Jul 29.
• [450] Chromosome-associated protein D3 promotes bacterial clearance in human intestinal epithelial cells by repressing expression of amino acid transporters.Gastroenterology. 2015 Jun;148(7):1405-1416.e3. doi: 10.1053/j.gastro.2015.02.013. Epub 2015 Feb 18.
• [451] Identification of neuroglobin as a novel player in anti-bacterial responses in amphioxus.Dev Comp Immunol. 2017 Dec;77:157-165. doi: 10.1016/j.dci.2017.08.004. Epub 2017 Aug 10.
• [452] Ribonucleotide reductase NrdR as a novel regulator for motility and chemotaxis during adherent-invasive Escherichia coli infection.Infect Immun. 2015 Apr;83(4):1305-17. doi: 10.1128/IAI.02772-14. Epub 2015 Jan 20.
• [453] Perylenediimide-based glycoclusters as high affinity ligands of bacterial lectins: synthesis, binding studies and anti-adhesive properties.Org Biomol Chem. 2017 Dec 6;15(47):10037-10043. doi: 10.1039/c7ob02749d.
• [454] Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity.Nature. 2019 Sep;573(7772):69-74. doi: 10.1038/s41586-019-1485-8. Epub 2019 Aug 21.
• [455] The role of group IIA secretory phospholipase A2 (sPLA2-IIA) as a biomarker for the diagnosis of sepsis and bacterial infection in adults-A systematic review.PLoS One. 2017 Jul 3;12(7):e0180554. doi: 10.1371/journal.pone.0180554. eCollection 2017.
• [456] Redirection of SKN-1 abates the negative metabolic outcomes of a perceived pathogen infection.Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22322-22330. doi: 10.1073/pnas.1909666116. Epub 2019 Oct 14.
• [457] Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin (100-109) in sera of mice infected with bacteria.J Immunol Methods. 2013 Sep 30;395(1-2):54-62. doi: 10.1016/j.jim.2013.06.011. Epub 2013 Jul 4.
• [458] RAIN study: a protocol for a randomised controlled trial evaluating efficacy, safety and cost-effectiveness of intravenous-to-oral antibiotic switch therapy in neonates with a probable bacterial infection.BMJ Open. 2019 Jul 9;9(7):e026688. doi: 10.1136/bmjopen-2018-026688.
• [459] The interferon stimulated gene viperin, restricts Shigella. flexneri in vitro.Sci Rep. 2019 Oct 30;9(1):15598. doi: 10.1038/s41598-019-52130-8.
• [460] Th2 cytokines differentially regulate psoriasin expression in human nasal epithelia.Am J Rhinol Allergy. 2014 Nov-Dec;28(6):449-53. doi: 10.2500/ajra.2014.28.4087.
• [461] Organization and biology of the porcine serum amyloid A (SAA) gene cluster: isoform specific responses to bacterial infection.PLoS One. 2013 Oct 11;8(10):e76695. doi: 10.1371/journal.pone.0076695. eCollection 2013.
• [462] Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration.BMC Genomics. 2014 Sep 10;15(1):726. doi: 10.1186/1471-2164-15-726.
• [463] Differential susceptibility of transgenic mice expressing human surfactant protein B genetic variants to Pseudomonas aeruginosa induced pneumonia.Biochem Biophys Res Commun. 2016 Jan 8;469(2):171-5. doi: 10.1016/j.bbrc.2015.11.089. Epub 2015 Nov 24.
• [464] SNX10 promotes phagosome maturation in macrophages and protects mice against Listeria monocytogenes infection.Oncotarget. 2017 Jul 27;8(33):53935-53947. doi: 10.18632/oncotarget.19644. eCollection 2017 Aug 15.
• [465] The STX6-VTI1B-VAMP3 complex facilitates xenophagy by regulating the fusion between recycling endosomes and autophagosomes.Autophagy. 2017 Jan 2;13(1):57-69. doi: 10.1080/15548627.2016.1241924. Epub 2016 Oct 28.
• [466] Shrimp TAB1 interacts with TAK1 and p38 and activates the host innate immune response to bacterial infection.Mol Immunol. 2017 Aug;88:10-19. doi: 10.1016/j.molimm.2017.05.016. Epub 2017 May 31.
• [467] In Vivo Biofilm Formation, Gram-Negative Infections and TAS2R38 Polymorphisms in CRSw NP Patients.Laryngoscope. 2018 Oct;128(10):E339-E345. doi: 10.1002/lary.27175. Epub 2018 Mar 23.
• [468] Genetic polymorphisms in TLR1, TLR2, TLR4, and TLR10 of Helicobacter pylori-associated gastritis: a prospective cross-sectional study in Thailand.Eur J Cancer Prev. 2018 Mar;27(2):118-123. doi: 10.1097/CEJ.0000000000000347.
• [469] Trim33 is essential for macrophage and neutrophil mobilization to developmental or inflammatory cues.J Cell Sci. 2017 Sep 1;130(17):2797-2807. doi: 10.1242/jcs.203471. Epub 2017 Jul 19.
• [470] The T300A Crohn's disease risk polymorphism impairs function of the WD40 domain of ATG16L1.Nat Commun. 2016 Jun 8;7:11821. doi: 10.1038/ncomms11821.
• [471] Failure of trafficking and antigen presentation by CD1 in AP-3-deficient cells.Immunity. 2002 May;16(5):697-706. doi: 10.1016/s1074-7613(02)00311-4.
• [472] Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.Immunology. 2010 Jun;130(2):288-95. doi: 10.1111/j.1365-2567.2009.03234.x. Epub 2010 Jan 19.
• [473] CD200-CD200R1 inhibitory signaling prevents spontaneous bacterial infection and promotes resolution of neuroinflammation and recovery after stroke.J Neuroinflammation. 2019 Feb 18;16(1):40. doi: 10.1186/s12974-019-1426-3.
• [474] Variation in genes of -glucan recognition pathway and susceptibility to opportunistic infections in HIV-positive patients.Immunol Invest. 2011;40(7-8):735-50. doi: 10.3109/08820139.2011.599088.
• [475] Studies on the interaction between GP-18-0-deficient neutrophils and vascular endothelium.Blood. 1982 Jul;60(1):160-5.
• [476] CYRI/FAM49B negatively regulates RAC1-driven cytoskeletal remodelling and protects against bacterial infection.Nat Microbiol. 2019 Sep;4(9):1516-1531. doi: 10.1038/s41564-019-0484-8. Epub 2019 Jul 8.
• [477] Increased expression of hepcidin and toll-like receptors 8 and 10 in viral keratitis.Cornea. 2011 Aug;30(8):899-904. doi: 10.1097/ICO.0b013e31820126e5.
• [478] Activation of the innate immunity in Drosophila by endogenous chromosomal DNA that escaped apoptotic degradation.Genes Dev. 2002 Oct 15;16(20):2662-71. doi: 10.1101/gad.1022802.
• [479] Novel DOCK8 gene mutations lead to absence of protein expression in patients with hyper-IgE syndrome.Immunol Res. 2016 Feb;64(1):260-71. doi: 10.1007/s12026-015-8745-y.
• [480] A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest. 2003 Oct;112(7):1108-15. doi: 10.1172/JCI18714.
• [481] Caspase-8 promotes c-Rel-dependent inflammatory cytokine expression and resistance against Toxoplasma gondii.Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11926-11935. doi: 10.1073/pnas.1820529116. Epub 2019 May 30.
• [482] Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa.Am J Trop Med Hyg. 2003 Dec;69(6):565-8.
• [483] Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic.Pediatr Pulmonol. 2006 Dec;41(12):1197-204. doi: 10.1002/ppul.20517.
• [484] Characterization of murine grancalcin specifically expressed in leukocytes and its possible role in host defense against bacterial infection.Biosci Biotechnol Biochem. 2004 Apr;68(4):894-902. doi: 10.1271/bbb.68.894.
• [485] Histidine-rich glycoprotein promotes bacterial entrapment in clots and decreases mortality in a mouse model of sepsis.Blood. 2010 Sep 30;116(13):2365-72. doi: 10.1182/blood-2010-02-271858. Epub 2010 Jun 29.
• [486] Mechanical Ventilation Impairs IL-17 Cytokine Family Expression in Ventilator-Associated Pneumonia.Int J Mol Sci. 2019 Oct 12;20(20):5072. doi: 10.3390/ijms20205072.
• [487] Mitochondrial reactive oxygen species enable proinflammatory signaling through disulfide linkage of NEMO.Sci Signal. 2019 Feb 12;12(568):eaar5926. doi: 10.1126/scisignal.aar5926.
• [488] Murine myeloid-derived suppressor cells are a source of elevated levels of interleukin-27 in early life and compromise control of bacterial infection.Immunol Cell Biol. 2019 May;97(5):445-456. doi: 10.1111/imcb.12224. Epub 2019 Feb 8.
• [489] A coding IRAK2 protein variant compromises Toll-like receptor (TLR) signaling and is associated with colorectal cancer survival.J Biol Chem. 2014 Aug 15;289(33):23123-23131. doi: 10.1074/jbc.M113.492934. Epub 2014 Jun 19.
• [490] Expression of the mu opioid receptor in the human immunodeficiency virus type 1 transgenic rat model.J Virol. 2007 Aug;81(16):8406-11. doi: 10.1128/JVI.00155-07. Epub 2007 Jun 6.
• [491] Porcine liver-expressed antimicrobial peptides, hepcidin and LEAP-2: cloning and induction by bacterial infection.Dev Comp Immunol. 2006;30(4):357-66. doi: 10.1016/j.dci.2005.06.004. Epub 2005 Jul 7.
• [492] Molecular and functional characterization of a mannose-binding lectin/ficolin-associated protein (MAp44) from Nile tilapia (Oreochromis niloticus) involved in the immune response to bacterial infection.Dev Comp Immunol. 2019 Dec;101:103438. doi: 10.1016/j.dci.2019.103438. Epub 2019 Jul 9.
• [493] Role of calcium in lipopolysaccharide-induced calcitonin gene expression in human adipocytes. Innate Immun. 2011 Aug;17(4):403-13. doi: 10.1177/1753425910377100. Epub 2010 Aug 3.
• [494] NODs: intracellular proteins involved in inflammation and apoptosis.Nat Rev Immunol. 2003 May;3(5):371-82. doi: 10.1038/nri1086.
• [495] IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation.Cell. 2018 May 3;173(4):920-933.e13. doi: 10.1016/j.cell.2018.02.055. Epub 2018 Mar 22.
• [496] Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis.Hum Immunol. 2011 Apr;72(4):348-54. doi: 10.1016/j.humimm.2011.01.008. Epub 2011 Jan 21.
• [497] Dehydration triggers ecdysone-mediated recognition-protein priming and elevated anti-bacterial immune responses in Drosophila Malpighian tubule renal cells.BMC Biol. 2018 May 31;16(1):60. doi: 10.1186/s12915-018-0532-5.
• [498] Differential expression of peptidoglycan recognition protein 2 in the skin and liver requires different transcription factors.J Biol Chem. 2006 Jul 28;281(30):20738-20748. doi: 10.1074/jbc.M601017200. Epub 2006 May 19.
• [499] Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection.J Immunol. 2001 Aug 1;167(3):1778-86. doi: 10.4049/jimmunol.167.3.1778.
• [500] The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma.J Natl Cancer Inst. 2011 Nov 16;103(22):1696-712. doi: 10.1093/jnci/djr360. Epub 2011 Oct 24.
• [501] Prokineticin 1 induces inflammatory response in human myometrium: a potential role in initiating term and preterm parturition.Am J Pathol. 2011 Dec;179(6):2709-19. doi: 10.1016/j.ajpath.2011.08.029. Epub 2011 Oct 6.
• [502] STING SNP R293Q Is Associated with a Decreased Risk of Aging-Related Diseases.Gerontology. 2019;65(2):145-154. doi: 10.1159/000492972. Epub 2018 Oct 26.
• [503] HLH-30/TFEB-mediated autophagy functions in a cell-autonomous manner for epithelium intrinsic cellular defense against bacterial pore-forming toxin in C. elegans.Autophagy. 2017 Feb;13(2):371-385. doi: 10.1080/15548627.2016.1256933. Epub 2016 Nov 22.
• [504] Unconventional autophagy mediated by the WD40 domain of ATG16L1 is derailed by the T300A Crohn disease risk polymorphism.Autophagy. 2016 Nov;12(11):2254-2255. doi: 10.1080/15548627.2016.1216303. Epub 2016 Aug 19.
• [505] Screening in planarians identifies MORN2 as a key component in LC3-associated phagocytosis and resistance to bacterial infection.Cell Host Microbe. 2014 Sep 10;16(3):338-50. doi: 10.1016/j.chom.2014.08.002.